


(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
15 March 2001 (15.03.2001)

PCT

(10) International Publication Number
WO 01/17999 A2

- (51) International Patent Classification⁷: C07D 471/04, A61K 31/437, A61P 25/00 // (C07D 471/04, 249:00, 221:00)
- (21) International Application Number: PCT/EP00/08372
- (22) International Filing Date: 28 August 2000 (28.08.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
99117578.7 6 September 1999 (06.09.1999) EP
- (71) Applicant: F. HOFFMANN-LA ROCHE AG [CH/CH];
124, Grenzacherstrasse, CH-4070 Basle (CH).
- (72) Inventors: HUBER TROTTMANN, Gerda; Hollen-
strasse 211, CH-4247 Grindel (CH). HUNKELER,
Walter; 32, Im Stigler, CH-4312 Magden (CH).
JAKOB-ROETNE, Roland; Oberer Baselblick 37,
79595 Inzlingen (DE). KILPATRICK, Gavin, John;
Lennox House, Caxton End, Eltisley, Cambridgeshire
PE19 4TJ (GB). NETTEKOVEN, Matthias, Heinrich;
Bandweg 10, 79639 Grenzach-Wyhlen (DE). RIEMER,
Claus; Optizstrasse 5, 79110 Freiburg (DE).
- (74) Agent: POPPE, Regina; 124 Grenzacherstrasse,
CH-4070 Basle (CH).
- (81) Designated States (*national*): AE, AL, AM, AT, AU, AZ,
BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE,
ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,
KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ,
VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— Without international search report and to be republished
upon receipt of that report.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: AMINO-TRIAZOLOPYRIDINE DERIVATIVES




(57) Abstract: The invention relates to compounds of formula (I) wherein R¹ is a 5 or 6 membered heteroaryl group, containing 1 to 3 heteroatoms, selected from N, O or S, and which groups are optionally substituted by one or two substituents, which are lower alkyl, -(CH₂)_nOH, halogen or lower alkoxy, and wherein the heteroaryl groups may be optionally linked to the pyrazole ring via an alkylene or alkenylene group, or is phenyl, optionally substituted by one or two substituents being lower alkyl, hydroxy-lower alkyl,

halogen, hydroxy or lower alkoxy or is -O(CH₂)_nphenyl, benzofuryl, indolyl or benzothiophenyl, or is -S-lower alkyl; R² and R⁴ are independently from each other hydrogen, cyano or -S(O)₂-phenyl; R³ is hydrogen, halogen or is a 5 or 6 membered heteroaryl group, containing 1 to 3 heteroatoms, selected from N, O or S, and which groups are optionally substituted by one or two substituents, which are lower alkyl, -(CH₂)_n-aryl, hydroxy, halogen, lower alkoxy, morpholinyl, amino, lower alkylamino or -C(O)NR'₂, and wherein R' is lower alkyl or hydrogen, or is phenyl, optionally substituted by one or two substituents being halogen, lower alkyl, lower alkoxy, amino, di-lower alkyl amino, CF₃, -OCF₃, -NHC(O)lower alkyl, cyano, -C(O)-lower alkyl, -C(O)O-lower alkyl, -S-lower alkyl, -S(O)₂NH-phenyl, -S(O)₂-methylpiperazinyl; or is -NR'R'', wherein R' and R'' are independently from each other hydrogen, -(CH₂)_nphenyl, which phenyl ring is optionally substituted by halogen or lower alkoxy, -CH(lower alkyl)-phenyl, indan-1-yl, 1,2,3,4-tetrahydro-naphthalen, or cycloalkyl; or is -O-phenyl, which phenyl ring is optionally substituted by halogen, lower alkyl or lower alkoxy, -O-tetrahydronaphthalenyl or -O-CH₂-6-methyl-pyridin-2-yl; or is -benzo[1,3]dioxolyl, -1H-indol-5-yl, naphthyl, benzofuran-2-yl, 1,3,4,9-tetrahydro-b-carbolin-2-yl, piperidin-1-yl, pyrrolidin-1-yl, piperazin-4-yl-methyl or morpholinyl; R⁵ is -NR₂, wherein R may be the same or different and is hydrogen, lower alkyl, phenyl, benzyl, -CO-lower alkyl, -CO-lower alkoxy, -lower alkenyl, -CO(CH₂)_n-phenyl or -COO(CH₂)_n-phenyl, wherein the phenyl ring is optionally substituted by CF₃, lower alkoxy, halogen or lower alkyl, -CO(CH₂)₃-NHCO-lower alkoxy, -(CH₂)_n-phenyl, wherein the phenyl ring is optionally substituted by lower alkoxy, CF₃ or halogen, or is 4,5-dihydro-1H-imidazol-2-yl-benzoic acid, 1,4,5,6-tetrahydro-pyrimidin-2-yl-benzoic acid or 4,5,6,7-tetrahydro-1H-[1,3]diazepin-2-yl-benzoic acid; n is 0-4 and their pharmaceutically acceptable salts.

Amino-triazolopyridine derivatives

The present invention relates to compounds of the general formula



wherein

- 5 R^1 is a 5 or 6 membered heteroaryl group, containing 1 to 3 heteroatoms, selected from N, O or S, and which groups are optionally substituted by one or two substituents, which are lower alkyl, $-(CH_2)_nOH$, halogen or lower alkoxy, and wherein the heteroaryl groups may be optionally linked to the pyrazole ring via an alkylene or alkenyle group, or is
- 10 phenyl, optionally substituted by one or two substituents being lower alkyl, hydroxy-lower alkyl, halogen, hydroxy or lower alkoxy or is
- $-O(CH_2)_n$ phenyl, benzofuryl, indolyl or benzothiophenyl, or is
- $-S$ -lower alkyl;
- R^2 and R^4 are independently from each other hydrogen, cyano or $-S(O)_2$ -phenyl;
- 15 R^3 is hydrogen, halogen or is
- a 5 or 6 membered heteroaryl group, containing 1 to 3 heteroatoms, selected from N, O or S, and which groups are optionally substituted by one or two substituents, which are lower alkyl, $-(CH_2)_n$ -aryl, hydroxy, halogen, lower alkoxy, morpholinyl, amino, lower alkylamino or $-C(O)NR'_2$, and wherein R' is lower alkyl or hydrogen,
- 20 or is

phenyl, optionally substituted by one or two substituents being halogen, lower alkyl, lower alkoxy, amino, di-lower alkyl amino, CF_3 , $-\text{OCF}_3$, $-\text{NHC}(\text{O})$ lower alkyl, cyano, $-\text{C}(\text{O})$ -lower alkyl, $-\text{C}(\text{O})\text{O}$ -lower alkyl, $-\text{S}$ -lower alkyl, $-\text{S}(\text{O})_2\text{NH}$ -phenyl, $-\text{S}(\text{O})_2$ -methylpiperazinyl; or is

5 $-\text{NR}'\text{R}''$, wherein R' and R'' are independently from each other hydrogen, $-(\text{CH}_2)_n$ phenyl, which phenyl ring is optionally substituted by halogen or lower alkoxy, $-\text{CH}(\text{lower alkyl})$ -phenyl, indan-1-yl, 1,2,3,4-tetrahydro-naphthalen, or cycloalkyl; or is

10 $-\text{O}$ -phenyl, which phenyl ring is optionally substituted by halogen, lower alkyl or lower alkoxy, $-\text{O}$ -tetrahydronaphthalenyl or $-\text{O}-\text{CH}_2$ -6-methyl-pyridin-2-yl; or is

$-\text{benzo}[1,3]$ dioxolyl, $-\text{1H-indol-5-yl}$, naphthyl, benzofuran-2-yl, 1,3,4,9-tetrahydro-b-carbolin-2-yl, piperidin-1-yl, pyrrolidin-1-yl, piperazin-4-yl-methyl or morpholinyl;

15 R^5 is $-\text{NR}_2$, wherein R may be the same or different and is hydrogen, lower alkyl, phenyl, benzyl, $-\text{CO}$ -lower alkyl, $-\text{CO}$ -lower alkoxy, $-\text{lower alkenyl}$, $-\text{CO}(\text{CH}_2)_n$ -phenyl or $-\text{COO}(\text{CH}_2)_n$ -phenyl, wherein the phenyl ring is optionally substituted by CF_3 , lower alkoxy, halogen or lower alkyl, $-\text{CO}(\text{CH}_2)_3$ -NHCO-lower alkoxy, $-(\text{CH}_2)_n$ -phenyl, wherein the phenyl ring is optionally substituted by lower alkoxy, CF_3 or halogen, or is 4,5-dihydro-1H-imidazol-2-yl-benzoic acid, 20 1,4,5,6-tetrahydro-pyrimidin-2-yl-benzoic acid or 4,5,6,7-tetrahydro-1H-[1,3]diazepin-2-yl-benzoic acid;

n is 0 – 4

and to their pharmaceutically acceptable salts.

25 It has surprisingly been found that the compounds of general formula I are adenosine receptor ligands.

Adenosine modulates a wide range of physiological functions by interacting with specific cell surface receptors. The potential of adenosine receptors as drug targets was first reviewed in 1982. Adenosine is related both structurally and metabolically to the bioactive nucleotides adenosine triphosphate (ATP), adenosine diphosphate (ADP), adenosine 30 monophosphate (AMP) and cyclic adenosine monophosphate (cAMP); to the biochemical methylating agent S-adenosyl-L-methione (SAM); and structurally to the coenzymes NAD, FAD and coenzyme A; and to RNA. Together adenosine and these related compounds are

important in the regulation of many aspects of cellular metabolism and in the modulation of different central nervous system activities.

The receptores for adenosine have been classified as A₁, A_{2A}, A_{2B} and A₃ receptors, belonging to the family of G protein-coupled receptors. Activation of adenosine receptors by adenosine initiates signal transduction mechanism. These mechanisms are dependent on the receptor associated G protein. Each of the adenosine receptor subtypes has been classically characterised by the adenylate cyclase effector system, which utilises cAMP as a second messenger. The A₁ and A₃ receptors, coupled with G_i proteins inhibit adenylate cyclase, leading to a decrease in cellular cAMP levels, while A_{2A} and A_{2B} receptors couple to G_s proteins and activate adenylate cyclase, leading to an increase in cellular cAMP levels. It is known that the A₁ receptor system include the activation of phospholipase C and modulation of both potassium and calcium ion channels. The A₃ subtype, in addition to its association with adenylate cyclase, also stimulates phospholipase C and so activates calcium ion channels.

The A₁ receptor (326-328 amino acids) was cloned from various species (canine, human, rat, dog, chick, bovine, guinea-pig) with 90-95% sequence identity among the mammalian species. The A_{2A} receptor (409-412 amino acids) was cloned from canine, rat, human, guinea pig and mouse. The A_{2B} receptor (332 amino acids) was cloned from human and mouse with 45% homology of human A_{2B} with human A₁ and A_{2A} receptors. The A₃ receptor (317-320 amino acids) was cloned from human, rat, dog, rabbit and sheep.

The A₁ and A_{2A} receptor subtypes are proposed to play complementary roles in adenosine's regulation of the energy supply. Adenosine, which is a metabolic product of ATP, diffuses from the cell and acts locally to activate adenosine receptors to decrease the oxygen demand (A₁) or increase the oxygen supply (A_{2A}) and so reinstate the balance of energy supply: demand within the tissue. The actions of both subtypes is to increase the amount of available oxygen to tissue and to protect cells against damage caused by a short term imbalance of oxygen. One of the important functions of endogenous adenosine is preventing damage during traumas such as hypoxia, ischaemia, hypotension and seizure activity.

Furthermore, it is known that the binding of the adenosine receptor agonist to mast cells expressing the rat A₃ receptor resulted in increased inositol triphosphate and intracellular calcium concentrations, which potentiated antigen induced secretion of inflammatory mediators. Therefore, the A₃ receptor plays a role in mediating asthmatic attacks and other allergic responses.

Adenosine is also a neuromodulator, possessing global importance in the modulation of molecular mechanisms underlying many aspects of physiological brain function by mediating central inhibitory effects. An increase in neurotransmitter release follows traumas such as hypoxia, ischaemia and seizures. These neurotransmitters are ultimately responsible for neural degeneration and neural death, which causes brain damage or death of the individual. The adenosine A₁ agonists which mimic the central inhibitory effects of adenosine may therefore be useful as neuroprotective agents. Adenosine has been proposed as an endogenous anticonvulsant agent, inhibiting glutamate release from excitatory neurons and inhibiting neuronal firing. Adenosine agonists therefore may be used as antiepileptic agents. Adenosine antagonists stimulate the activity of the CNS and have proven to be effective as cognition enhancers. Selective A_{2a}-antagonists have therapeutic potential in the treatment of various forms of dementia, for example in Alzheimer's disease and are useful as neuroprotective agents. Adenosine A₂-receptor antagonists inhibit the release of dopamine from central synaptic terminals and reduce locomotor activity and consequently improve Parkinsonian symptoms. The central activities of adenosine are also implicated in the molecular mechanism underlying sedation, hypnosis, schizophrenia, anxiety, pain, respiration, depression and substance abuse. Drugs acting at adenosine receptors therefore have also therapeutic potential as sedatives, muscle relaxants, antipsychotics, anxiolytics, analgesics, respiratory stimulants and antidepressants.

An important role for adenosine in the cardiovascular system is as a cardioprotective agent. Levels of endogenous adenosine increase in response to ischaemia and hypoxia, and protect cardiac tissue during and after trauma (preconditioning). Adenosine agonists thus have potential as cardioprotective agents.

Adenosine modulates many aspects of renal function, including renin release, glomerular filtration rate and renal blood flow. Compounds, which antagonise the renal effects of adenosine, have potential as renal protective agents. Furthermore, adenosine A₃ and/or A_{2B} antagonists may be useful in the treatment of asthma and other allergic responses.

Numerous documents describe the current knowledge on adenosine receptors, for example the following publications:

- Bioorganic & Medicinal Chemistry, 6, (1998), 619-641,
- Bioorganic & Medicinal Chemistry, 6, (1998), 707-719,
- J. Med. Chem., (1998), 41, 2835-2845,
- J. Med. Chem., (1998), 41, 3186-3201,
- J. Med. Chem., (1998), 41, 2126-2133,
- J. Med. Chem., (1999), 42, 706-721,

J. Med. Chem., (1996), 39, 1164-1171,
Arch. Pharm. Med. Chem., 332, 39-41, (1999)

Objects of the present invention are compounds of formula I and their pharmaceutically acceptable salts per se and as pharmaceutically active substances, their
5 manufacture, medicaments based on a compound in accordance with the invention and their production as well as the use of compounds of formula I in the control or prevention of illnesses based on the modulation of the adenosine system, such as Alzheimer's disease, Parkinson's disease, neuroprotection, schizophrenia, anxiety, pain, respiration deficits, depression, asthma, allergic responses, hypoxia, ischaemia, seizure and substance abuse.
10 Furthermore, compounds of the present invention may be useful as sedatives, muscle relaxants, antipsychotics, antiepileptics, anticonvulsants and cardioprotective agents. The most preferred indications in accordance with the present invention are those, which base on the A_{2A} receptor antagonistic activity and which include disorders of the central nervous system, for example the treatment or prevention of certain depressive disorders,
15 neuroprotection and Parkinson's disease.

As used herein, the term "lower alkyl" denotes a saturated straight- or branched-chain alkyl group containing from 1 to 6 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, n-butyl, i-butyl, 2-butyl, t-butyl and the like. Preferred lower alkyl groups are groups with 1 - 4 carbon atoms.

20 As used herein, the term "lower alkenyl" denotes a unsaturated straight- or branched-chain alkyl group containing from 2 to 6 carbon atoms, for example, ethylen, propylen, isopropylen, n-butylen, i-butylen, 2-butylen, t-butylen and the like. Preferred lower alkyl groups are groups with 2 - 4 carbon atoms.

The term "cycloalkyl" denotes a saturated carbocyclic group, containing 3 – 6 carbon
25 atoms.

The term "halogen" denotes chlorine, iodine, fluorine and bromine.

The term "lower alkoxy" denotes a group wherein the alkyl residues is as defined above, and which is attached via an oxygen atom.

The term "5 or 6 membered heteroaryl group" denotes, for example furyl,
30 thiophenyl, thiazolyl, pyridinyl, tetrahydro-furanyl, 5,6-dihydro-4H-pyran-2-yl, isoxazol-5-yl, 4,5-dihydro-furan-2-yl, 5,6-dihydro-pyran-2-yl, pyrazol-1-yl, 1,2,4-triazol-1-yl, imidazol-1-yl and the like.

Preferred "aryl" groups are, for example phenyl or naphthyl groups.

The term "pharmaceutically acceptable acid addition salts" embraces salts with inorganic and organic acids, such as hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, citric acid, formic acid, fumaric acid, maleic acid, acetic acid, succinic acid, tartaric acid, methane-sulfonic acid, p-toluenesulfonic acid and the like.

- 5 Exemplary preferred compounds, showing activity on the A_{2A} receptor, are compounds of formula I, wherein R⁵ is an unsubstituted amino group and R¹ is furyl, for example the following compounds:
- 2-furan-2-yl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
 2-furan-2-yl-7-pyridin-3-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
 10 2-furan-2-yl-7-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
 7-(3,5-bis-trifluoromethyl-phenyl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
 7-(3,5-dichloro-phenyl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
 7-(4-chloro-phenyl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
 2-furan-2-yl-7-(2-methyl-pyridin-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
 15 7-(2-ethyl-pyridin-4-yl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
 2-furan-2-yl-7-(2-propyl-pyridin-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
 2-furan-2-yl-7-(2-isopropyl-pyridin-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
 7-(4-fluoro-phenyl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
 2-furan-2-yl-7-(1-oxy-pyridin-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
 20 5-amino-2-furan-2-yl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridine-6-carbonitrile,
 7-(3-amino-phenyl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
 7-(3,4-dimethoxy-phenyl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
 7-(3,4-dichloro-phenyl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
 7-(3-fluoro-phenyl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
 25 1-[3-(5-amino-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-phenyl]-ethanone,
 7-(2-fluoro-phenyl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
 2-furan-2-yl-7-m-tolyl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
 2-furan-2-yl-7-(4-methylsulfanyl-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
 2-furan-2-yl-7-thiophen-3-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
 30 2-furan-2-yl-7-(3-trifluoromethyl-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
 2-furan-2-yl-7-(3-methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
 N-[3-(5-amino-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-phenyl]-acetamide,
 2-furan-2-yl-7-(1H-indol-5-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
 N-[4-(5-amino-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methyl-phenyl]-
 35 acetamide,
 2-furan-2-yl-7-piperidin-1-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
 2-furan-2-yl-7-pyrrolidin-1-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
 2-furan-2-yl-7-(4-methyl-piperazin-1-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,

- N7-(2-chloro-benzyl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridine-5,7-diamine,
 2-furan-2-yl-N7-(2-methoxy-benzyl)-[1,2,4]triazolo[1,5-a]pyridine-5,7-diamine,
 2-furan-2-yl-N7-(1-phenyl-ethyl)-[1,2,4]triazolo[1,5-a]pyridine-5,7-diamine,
 7-(5-butyl-pyridin-2-yl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
 5 7-(2-fluoro-pyridin-4-yl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
 7-(5-chloro-pyridin-2-yl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine or
 2-furan-2-yl-7-(6-methoxy-pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine.

Further preferred compounds are those, wherein R⁵ is an unsubstituted amino group and R¹ is methyl substituted furyl, for example the following compounds:

- 10 7-(4-chloro-phenyl)-2-(5-methyl-furan-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
 7-(3-methoxy-phenyl)-2-(5-methyl-furan-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
 7-(3,4-dimethoxy-phenyl)-2-(5-methyl-furan-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
 N-{3-[5-amino-2-(5-methyl-furan-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-7-yl]-phenyl}-
 15 acetamide or
 N-{4-[5-amino-2-(5-methyl-furan-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-7-yl]-phenyl}-acetamide.

Further preferred compounds are those, wherein R⁵ is an unsubstituted amino group and R¹ is pyridin-2-yl, for example the following compounds:

- 20 7-(4-fluoro-phenyl)-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
 7-(3-methoxy-phenyl)-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
 7-(3-amino-phenyl)-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
 7-(2-ethyl-pyridin-4-yl)-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
 7-(2-methyl-pyridin-4-yl)-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
 25 7-(5-ethyl-pyridin-2-yl)-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
 2,7-di-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
 7-(5-chloro-pyridin-2-yl)-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine or
 7-(6-chloro-pyridin-2-yl)-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine.

- Preferred compounds are further those, wherein R⁵ is an unsubstituted amino group and R¹ is 5,6-dihydro-furan-2-yl, for example the following compounds:

- 30 7-(3,4-dichloro-phenyl)-2-(4,5-dihydro-furan-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
 2-(4,5-dihydro-furan-2-yl)-7-(3-fluoro-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
 2-(4,5-dihydro-furan-2-yl)-7-(4-fluoro-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
 35 2-(4,5-dihydro-furan-2-yl)-7-m-tolyl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine or
 2-(4,5-dihydro-furan-2-yl)-7-(3-trifluoromethyl-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine.

Preferred compounds are further those, wherein R⁵ is an unsubstituted amino group and R¹ is pyrazol-1-yl, for example the following compound:

2-pyrazol-1-yl-7-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine.

Exemplary preferred compounds are those, wherein R⁵ is a substituted amino group, and R¹ is phenyl, for example the following compounds:

but-3-enyl-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-amine,

ethyl-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-amine,

(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-carbamic acid ethyl ester,

N-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-4-trifluoromethyl-

10 benzamide,

2-(2-chloro-phenyl)-N-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-acetamide,

2-(2,4-dichloro-phenyl)-N-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-acetamide,

15 N-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-2-(2-trifluoromethyl-phenyl)-acetamide,

N-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-2-(4-trifluoromethyl-phenyl)-acetamide,

3-phenyl-N-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-propionamide,

20 N-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-2-o-tolyl-acetamide,

2-(2-bromo-phenyl)-N-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-acetamide,

2-(2-iodo-phenyl)-N-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-acetamide,

25 3-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylcarbamoyl)-propyl-carbamic acid tert-butyl ester,

2-(2-chloro-phenyl)-ethyl-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-amine,


2-(2,4-dichloro-phenyl)-ethyl-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-amine,

30 (2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-(4-trifluoromethyl-benzyl)-amine,


(3-phenyl-propyl)-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-amine or diethyl-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-amine.

35 The present compounds of formula I and their pharmaceutically acceptable salts can be prepared by methods known in the art, for example, by processes described below, which process comprises


a) reacting a compound of formula



with a compound of formula




5 to a compound of formula



wherein $R^1 - R^4$ have the significances given above, or

- b) substituting one or two hydrogen atoms of the amino group in formula I-1 by R, which is lower alkyl, phenyl, benzyl, -CO-lower alkyl, -CO-lower alkoxy, -lower alkenyl, -
- 10 CO(CH₂)_n-phenyl or -COO(CH₂)_n-phenyl, wherein the phenyl ring is optionally substituted by CF₃, lower alkoxy, halogen or lower alkyl, -CO(CH₂)₃-NHCO-lower alkoxy, -(CH₂)_n-phenyl, wherein the phenyl ring is optionally substituted by lower alkoxy, CF₃ or halogen.

c) reacting a compound of formula



15

with a compound of formula



to a compound of formula I-1, wherein $R^1 - R^4$ have the significances given above, or

d) modifying one or more substituents $R^1 - R^5$ within the definitions given above,

and

if desired, converting the compounds obtained into pharmaceutically acceptable acid addition salts.

5 In accordance with process variant a) to a boiling suspension of sodiumhydride and THF is added a mixture of compounds of formula II and III, for example 3-benzenesulfonylmethyl-5-furan-2-yl-1H-[1,2,4]triazole and 3-(4-pyridinyl)-2-propenenitrile or 3-benzenesulfonylmethyl-5-furan-2-yl-1H-[1,2,4]triazole and (E)-3-(2-methyl-pyridin-4-yl)-acrylonitril. The reaction is carried out at boiling temperature.

10 The substitution of one or two hydrogen atoms of the amino group in formula I-1 by R, wherein R has the significance given above, is carried out by conventional methods, for example with corresponding acetyl- or benzoyl chlorides.


A further method for the preparation of compounds of formula I is described in process variant c). In accordance with this method, a mixture of a compound of formula
15 IV, for example 7-bromo-2-phenyl-[1,2,4]pyridin-5-ylamine and of a compound of formula V, for example p-tolyl-boronic acid, is treated with tetrakis-(triphenylphosphine)palladium and heated to about 90°C. The reaction is carried out in the presence of a base, for example in Na_2CO_3 , Cs_2CO_3 or triethylamine.

The salt formation is effected at room temperatures in accordance with methods
20 which are known per se and which are familiar to any person skilled in the art. Not only salts with inorganic acids, but also salts with organic acids came into consideration. Hydrochlorides, hydrobromides, sulphates, nitrates, citrate, acetates, maleates, succinates, methan-sulphonates, p-toluenesulphonates and the like are examples of such salts.

In Examples 1 – 351 and in the following schemes 1 and 2 the preparation of
25 compounds of formula I is described in more detail.


The starting materials of formulae III, V, VI, VIII and X are known compounds or may be prepared according to methods known in the art.

Scheme 1



The meaning of the substituents $\text{R}^1 - \text{R}^4$ is given above.

Scheme 2



The compounds of formula I and their pharmaceutically usable addition salts possess valuable pharmacological properties. Specifically, it has been found that the compounds of the present invention are adenosine receptor ligands.

The compounds were investigated in accordance with the tests given hereinafter.

Human adenosine A_{2A} receptor

The human adenosine A_{2A} receptor was recombinantly expressed in chinese hamster ovary (CHO) cells using the semliki forest virus expression system. Cells were harvested, washed twice by centrifugation, homogenised and again washed by centrifugation. The final washed membrane pellet was suspended in a Tris (50mM) buffer containing 120mM NaCl, 5mM KCl, 2mM CaCl₂ and 10mM MgCl₂ (pH 7.4) (buffer A). The [³H]-SCH-58261 (Dionisotti et al., 1997, Br J Pharmacol 121, 353; 1nM) binding assay was carried out in 96-well plates in the presence of 2.5µg of membrane protein, 0.5mg of Ysi-poly-l-lysine SPA beads and 0.1U adenosine deaminase in a final volume of 200µl of buffer A. Non-specific binding was defined using xanthine amine congener (XAC; 2µM). Compounds were tested at 10 concentrations from 10µM-0.3nM. All assays were conducted in duplicate and repeated at least two times. Assay plates were incubated for 1hour at room temperature before centrifugation and then bound ligand determined using a Packard Topcount scintillation counter. IC₅₀ values were calculated using a non-linear curve fitting program and Ki values calculated using the Cheng-Prusoff equation.

In accordance with the invention, it has been shown that compounds of formula I have a high affinity toward the A_{2A} receptor. The preferred compounds have an pKi value in the range of 7.5 to 8.4 in the human A_{2A} binding. In the table below are described some specific pKi values of preferred compounds.

Compound	hA _{2A} pKi
2-(4,5-Dihydro-furan-2-yl)-7-m-tolyl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	7.5
7-(2-Methyl-pyridin-4-yl)-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	7.5
2-(4,5-Dihydro-furan-2-yl)-7-(3-fluoro-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	7.6
7-(3,4-Dimethoxy-phenyl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	7.6
7-(2-Fluoro-pyridin-4-yl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	7.8
2-Furan-2-yl-7-(6-methoxy-pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	7.9

2-Furan-2-yl-7-m-tolyl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	8.0
7-(3,4-Dichloro-phenyl)-2-(4,5-dihydro-furan-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	8.1
7-(2-Ethyl-pyridin-4-yl)-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	8.1

The compounds of formula I and the pharmaceutically acceptable salts of the compounds of formula I can be used as medicaments, e.g. in the form of pharmaceutical preparations. The pharmaceutical preparations can be administered orally, e.g. in the form of tablets, coated tablets, dragées, hard and soft gelatine capsules, solutions, emulsions or
5 suspensions. The administration can, however, also be effected rectally, e.g. in the form of suppositories, parenterally, e.g. in the form of injection solutions.

The compounds of formula I can be processed with pharmaceutically inert, inorganic or organic carriers for the production of pharmaceutical preparations. Lactose, corn starch or derivatives thereof, talc, stearic acids or its salts and the like can be used, for example, as
10 such carriers for tablets, coated tablets, dragées and hard gelatine capsules. Suitable carriers for soft gelatine capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like. Depending on the nature of the active substance no carriers are, however, usually required in the case of soft gelatine capsules. Suitable carriers for the production of solutions and syrups are, for example, water, polyols, glycerol, vegetable oil
15 and the like. Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like.

The pharmaceutical preparations can, moreover, contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still
20 other therapeutically valuable substances.

Medicaments containing a compound of formula I or a pharmaceutically acceptable salt thereof and a therapeutically inert carrier are also an object of the present invention, as is a process for their production, which comprises bringing one or more compounds of formula I and/or pharmaceutically acceptable acid addition salts and, if desired, one or
25 more other therapeutically valuable substances into a galenical administration form together with one or more therapeutically inert carriers.

In accordance with the invention compounds of formula I as well as their pharmaceutically acceptable salts are useful in the control or prevention of illnesses based on the adenosine receptor antagonistic activity, such as Alzheimer's disease, Parkinson's disease, neuroprotection, schizophrenia, anxiety, pain, respiration deficits, depression, asthma, allergic responses, hypoxia, ischaemia, seizure and substance abuse. Furthermore, compounds of the present invention may be useful as sedatives, muscle relaxants, antipsychotics, antiepileptics, anticonvulsants and cardioprotective agents and for the production of corresponding medicaments.

The most preferred indications in accordance with the present invention are those, which include disorders of the central nervous system, for example the treatment or prevention of certain depressive disorders, neuroprotection and Parkinson's disease.

The dosage can vary within wide limits and will, of course, have to be adjusted to the individual requirements in each particular case. In the case of oral administration the dosage for adults can vary from about 0.01 mg to about 1000 mg per day of a compound of general formula I or of the corresponding amount of a pharmaceutically acceptable salt thereof. The daily dosage may be administered as single dose or in divided doses and, in addition, the upper limit can also be exceeded when this is found to be indicated.

Tablet Formulation (Wet Granulation)

	<u>Item</u>	<u>Ingredients</u>	<u>mg/tablet</u>			
			5 mg	25 mg	100 mg	500 mg
20	1.	Compound of formula I	5	25	100	500
	2.	Lactose Anhydrous DTG	125	105	30	150
	3.	Sta-Rx 1500	6	6	6	30
	4.	Microcrystalline Cellulose	30	30	30	150
25	5.	Magnesium Stearate	1	1	1	1
		Total	167	167	167	831

Manufacturing Procedure

1. Mix items 1, 2, 3 and 4 and granulate with purified water.
2. Dry the granules at 50°C.
- 30 3. Pass the granules through suitable milling equipment.
4. Add item 5 and mix for three minutes; compress on a suitable press.

Capsule Formulation

	<u>Item</u>	<u>Ingredients</u>	<u>mg/capsule</u>			
			5 mg	25 mg	100 mg	500 mg
	1.	Compound of formula I	5	25	100	500
5	2.	Hydrous Lactose	159	123	148	---
	3.	Corn Starch	25	35	40	70
	4.	Talc	10	15	10	25
	5.	Magnesium Stearate	1	2	2	5
		Total	200	200	300	600

10 Manufacturing Procedure

1. Mix items 1, 2 and 3 in a suitable mixer for 30 minutes.
2. Add items 4 and 5 and mix for 3 minutes.
3. Fill into a suitable capsule.

Example 115 2-Furan-2-yl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylaminea) Furan-2-carboxylic acid (1-amino-2-benzenesulfonyl-ethylidene)-hydrazide

A suspension of 85.0g (0.32mol) 2-(phenylsulfonyl)-ethanimidic acid ethyl ester hydrochloride in 700 ml chloroform was treated with 320 ml 1N aqueous sodium hydroxide. 100 ml of a saturated aqueous sodiumbicarbonate solution was added and the mixture was extracted with chloroform. The extracts were combined and dried with sodium sulfate and the solvents were distilled off under reduced pressure. The resulting colorless oil was stirred together with 42.6g (0.34mol) 2-furancarboxylic acid hydrazide in 600ml chloroform for 24 hours at 50°C. The resulting precipitate was filtered off and dried. A quantitative yield of furan-2-carboxylic acid (1-amino-2-benzenesulfonyl-ethylidene)-hydrazide was obtained as pale crystals, mp. 195°C (decomposition), MS m/e (%): 308 (M+H⁺, 100).

b) 3-Benzenesulfonylmethyl-5-furan-2-yl-1H-[1,2,4]triazole

105g (0.34mol) Furan-2-carboxylic acid (1-amino-2-benzenesulfonyl-ethylidene)-hydrazide were heated at 200°C for 20 minutes. The molten mass was then cooled, dissolved in 250 ml hot ethanol and stirred overnight at room temperature. The

precipitated crystals were filtered off and dried to yield 65.7 g (66%) 3-benzenesulfonylmethyl-5-furan-2-yl-1H-[1,2,4]triazole as white crystals with mp. 185-186°C, MS m/e (%): 290 (M+H⁺, 100).

c) 2-Furan-2-yl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

- 5 To a boiling suspension of 5.9g(0.12mol) sodiumhydride (55%) in 100 ml tetrahydrofuran was slowly added over a period of 6 hours a mixture of 10.1g (0.035mol) 3-benzenesulfonylmethyl-5-furan-2-yl-1H-[1,2,4]triazole and 4.56g (0.035mol) 3-(4-pyridinyl)-2-propenenitrile in 400 ml tetrahydrofuran. Boiling was continued for 15 hours and then 50ml methanol were added at room temperature. Evaporation of the solvent and
- 10 chromatography on silicagel with dichloromethane/methanol 95/5 gave 1.3g (13%) 2-furan-2-yl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine as yellow crystals with mp. 294-296°C.

Example 2

2-Furan-2-yl-7-pyridin-3-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

- 15 The title compound, MS m/e (%): 277 (M⁺, 100), was prepared in accordance with the general method of example 1 from 3-benzenesulfonylmethyl-5-furan-2-yl-1H-[1,2,4]triazole and 3-(3-pyridinyl)-2-propenenitrile.

Example 3

2-Furan-2-yl-7-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

- 20 The title compound, MS m/e (%): 278 (M+H⁺, 100), was prepared in accordance with the general method of example 1 from 3-benzenesulfonylmethyl-5-furan-2-yl-1H-[1,2,4]triazole and 3-(2-pyridinyl)-2-propenenitrile.

Example 4

7-(3,5-Bis-trifluoromethyl-phenyl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

- 25 The title compound, MS m/e (%): 412 (M⁺, 100), was prepared in accordance with the general method of example 1 from 3-benzenesulfonylmethyl-5-furan-2-yl-1H-[1,2,4]triazole and 3-[3,5-bis(trifluoromethyl)phenyl]acrylonitrile.

Example 5

7-(3,5-Dichloro-phenyl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

a) Mixture of (E)- and (Z)-3-(3,5-dichloro-phenyl)-acrylonitrile

To a suspension of 0.68g (0.024mol) sodiumhydride in 20 ml tetrahydrofurane and 20 ml dimethylformamide were added 5.79g (0.017mol) (cyanomethyl)triphenylphosphonium chloride. After sirring for 1 hour at room temperature a solution of 3.00g (0.017mol) 3,5-dichlorobenzaldehyde in 3 ml tetrahydrofuran were added and stirring was continued for 15 hours. Then 2 ml methanol were added, the solvents were evaporated and the residue chromatographed on silicagel with ethylacetate/hexane 2/8 to yield 1.17g (35%) (E)- and (Z)-3-(3,5-dichloro-phenyl)-acrylonitrile as white crystals. MS m/e (%): 197 (M^+ , 100).

b) The title compound, mp. 257-260°C and MS m/e (%): 345 ($M+H^+$, 100), was prepared in accordance with the general method of example 1 from 3-benzenesulfonylmethyl-5-furan-2-yl-1H-[1,2,4]triazole and 3-(3,5-dichloro-phenyl)-acrylonitrile

Example 6

7-(4-Chloro-phenyl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

0.7g (0.015mol) sodiumhydride (55%) were added to a solution of 1.50g (0.005mol) 3-benzenesulfonylmethyl-5-furan-2-yl-1H-[1,2,4]triazole in 50 ml tetrahydrofuran. The mixture was refluxed and 0.85g (0.005mol) 3-(4-chlorophenyl)-2-propenenitrile in 30 ml tetrahydrofuran were added during aperiod of 5.5 hours. Boiling was continued for 30 minutes and then 20ml methanol were added at room temperature. Evaporation of the solvent and chromatography on silicagel with dichloromethane/methanol 99/1 gave 0.57g (35%) 7-(4-chloro-phenyl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine as pale crystals. MS m/e (%): 311 ($M+H^+$, 100).

Example 7

2-Furan-2-yl-7-(2-methyl-pyridin-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

The title compound, mp. 100-101°C and MS (EI) m/e (%): 291 (M^+ , 100), was prepared in accordance with the general method of example 1 from 3-benzenesulfonylmethyl-5-furan-2-yl-1H-[1,2,4]triazole and (E)-3-(2-methyl-pyridin-4-yl)-acrylonitrile.

Example 8

7-(2-Ethyl-pyridin-4-yl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

a) (E)-3-(2-Ethyl-pyridin-4-yl)-acrylonitrile

To a suspension of 1.79g (0.041mol) sodiumhydride in 50 ml tetrahydrofurane and 50 ml dimethylformamide were added 13.9g (0.041mol) (cyanomethyl)triphenylphosphonium

chloride. After stirring for 1 hour at room temperature a solution of 5.54g (0.041mol) 2-ethyl-4-pyridinecarboxaldehyde in 10 ml tetrahydrofuran were added and stirring was continued for 15 hours. Then 10 ml methanol were added, the solvents were evaporated and the residue chromatographed on aluminiumoxide with dichloromethane to yield 1.63g (25%) (E)-3-(2-ethyl-pyridin-4-yl)-acrylonitrile as white waxy solid. MS m/e (%): 158 (M⁺, 100).

b) The title compound, mp. 184-186°C and MS m/e (%): 305 (M⁺, 100), was prepared in accordance with the general method of example 1 from 3-benzenesulfonylmethyl-5-furan-2-yl-1H-[1,2,4]triazole and (E)-3-(2-ethyl-pyridin-4-yl)-acrylonitrile.

10

Example 9

2-Furan-2-yl-7-(2-propyl-pyridin-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

a) 3-(2-Propyl-pyridin-4-yl)-acrylonitrile

To a suspension of 1.39g (0.03mol) sodiumhydride in 40 ml tetrahydrofurane and 40 ml dimethylformamide were added 10.13g (0.03mol) (cyanomethyl)triphenylphosphonium chloride. After stirring for 1 hour at room temperature a solution of 4.48g (0.03mol) 2-propyl-4-pyridinecarboxaldehyde in 15 ml tetrahydrofuran were added and stirring was continued for 15 hours. Then 10 ml methanol were added, the solvents were evaporated and the residue chromatographed on aluminiumoxide with dichloromethane to yield 2.42g 3-(2-propyl-pyridin-4-yl)-acrylonitrile as yellow oil. MS m/e (%): 173 (M+H⁺, 100).

b) The title compound, MS m/e (%): 319 (M⁺, 100), was prepared in accordance with the general method of example 1 from 3-benzenesulfonylmethyl-5-furan-2-yl-1H-[1,2,4]triazole and 3-(2-propyl-pyridin-4-yl)-acrylonitrile.

Example 10

2-Furan-2-yl-7-(2-isopropyl-pyridin-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

a) 3-(2-Isopropyl-pyridin-4-yl)-acrylonitrile

To a suspension of 6.55g (0.15mol) sodiumhydride in 220 ml tetrahydrofurane and 220 ml dimethylformamide were added 50.7g (0.15mol) (cyanomethyl)triphenylphosphonium chloride. After stirring for 1 hour at room temperature a solution of 22.4g (0.15mol) 2-isopropyl-4-pyridinecarboxaldehyde in 50 ml tetrahydrofuran were added and stirring was continued for 15 hours. Then 10 ml methanol were added, the solvents were evaporated and the residue chromatographed on aluminiumoxide with dichloromethane to yield 2.96g 3-(2-isopropyl-pyridin-4-yl)-acrylonitrile as colorless oil. MS m/e (%): 172 (M⁺, 100).

b) The title compound, MS m/e (%): 320 ($M+H^+$, 100), was prepared in accordance with the general method of example 1 from 3-benzenesulfonylmethyl-5-furan-2-yl-1H-[1,2,4]triazole and 3-(2-isopropyl-pyridin-4-yl)-acrylonitrile.

Example 11

5 7-(4-Fluoro-phenyl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

The title compound, MS m/e (%): 295 ($M+H^+$, 100), was prepared in accordance with the general method of example 1 from 3-benzenesulfonylmethyl-5-furan-2-yl-1H-[1,2,4]triazole and 3-(4-fluoro-phenyl)-acrylonitrile.

Example 12

2-Furan-2-yl-7-(1-oxy-pyridin-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

a) 3-(1-Oxy-pyridin-4-yl)-acrylonitrile

A mixture of 10.4g (0.08mol) 3-(4-pyridinyl)-2-propenenitrile, 0.1g (0.0006mol) methyltrioxorhenium, 15.5ml hydrogenperoxide and 300 ml dichloromethane were stirred at room temperature for 6 hours. Then a small quantity of manganese dioxide was added and stirring was continued for one hour. After extraction with dichloromethane/water the organic phase was dried with sodium sulfate and the solvent was distilled off. Chromatography on silicagel with dichloromethane/methanol 95/5 gave 3.3g (28%) 3-(1-oxy-pyridin-4-yl)-acrylonitrile (E:Z=1:1), MS m/e (%): 146 (M^+ , 100).

b) 2-Furan-2-yl-7-(1-oxy-pyridin-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

The title compound, MS m/e (%): 294 ($M+H^+$, 100), was prepared in accordance with the general method of example 1 from 3-benzenesulfonylmethyl-5-furan-2-yl-1H-[1,2,4]triazole and 3-(1-oxy-pyridin-4-yl)-acrylonitrile.

Example 13

5-Amino-2-furan-2-yl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridine-6-carbonitrile

The title compound, MS m/e (%): 303 ($M+H^+$, 100), was prepared in accordance with the general method of example 1 from 3-benzenesulfonylmethyl-5-furan-2-yl-1H-[1,2,4]triazole and 4-pyridinylmethylen-propanedinitril.

Example 14

2-(5-Methyl-furan-2-yl)-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

a) 5-Methyl-furan-2-carboxylic acid (1-amino-2-benzenesulfonyl-ethylidene)-hydrazide

A suspension of 85.0g (0.32mol) 2-(phenylsulfonyl)-ethanimidic acid ethyl ester
5 hydrochloride in 700 ml chloroform was treated with 320 ml 1N aqueous sodium
hydroxide. 100 ml of a saturated aqueous sodiumbicarbonate solution was added and the
mixture was extracted with chloroform. The extracts were combined and dried with
sodium sulfate and the solvents were distilled off under reduced pressure. 17.8 g
(0.078Mol) of the resulting colorless oil was stirred together with 9.15 g (0.065mol) 5-
10 methyl-furan-2-carboxylic acid hydrazide in 115ml chloroform for 24 hours at 50°C. The
resulting precipitate was filtered off and dried. 17.3g of 5-methyl-furan-2-carboxylic acid
(1-amino-2-benzenesulfonyl-ethylidene)-hydrazide was obtained as white crystals. Mp.:
219-220°C.

b) 3-Benzenesulfonylmethyl-5-methyl-furan-2-yl-1H-[1,2,4]triazole

15 8.0 g (0.025mol) 5-Methyl-furan-2-carboxylic acid (1-amino-2-benzenesulfonyl-
ethylidene)-hydrazide were heated at 210°C for 20 minutes. The molten mass was then
cooled, dissolved in 250 ml hot ethanol and stirred overnight at room temperature. The
precipitated crystals were filtered off and subjected to column chromatography on silicagel
with ethyl acetate hexanes 1:1 and 3:2 to yield 6.76 g (90%) 3-benzenesulfonylmethyl-5-
20 methyl-furan-2-yl-1H-[1,2,4]triazole as white crystals. MS (EI) m/e (%): 303 (M+H⁺, 16).

c) 2-(5-Methyl-furan-2-yl)-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

The title compound was prepared in accordance with the general method of example 1
from 3-benzenesulfonylmethyl-5-methyl-furan-2-yl-1H-[1,2,4]triazole and 3-(4-
pyridinyl)-2-propenenitrile. Mp.: 270-272°C (dec.).

25

Example 15

N-[2-(5-Methyl-furan-2-yl)-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl]-acetamide

The title compound was obtained as a byproduct in the reaction above and isolated after
chromatographic purification on SiO₂ with 1% MeOH in dichloromethan. Mp.: 257-
259°C.

30

Example 16

2-(4,5-Dimethyl-furan-2-yl)-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

a) 4,5-Dimethyl-furan-2-carboxylic acid (1-amino-2-benzenesulfonyl-ethylidene)-hydrazide

A suspension of 1.18g (0.004mol) 2-(phenylsulfonyl)-ethanimidic acid ethyl ester hydrochloride in 15 ml chloroform was treated with 6 ml 1N aqueous sodium hydroxide.

- 5 The mixture was extracted with dichloromethane. The extracts were combined and dried with magnesium sulfate and the solvents were distilled off under reduced pressure. The resulting colorless oil was stirred together with 0.68g (0.004mol) 4,5-dimethyl-furan-2-carboxylic acid hydrazide in 10ml chloroform for 24 hours at reflux temperature. Evaporation of the solvent and chromatography on silicagel with
- 10 dichloromethane/methanol 19/1 gave 1.14g (76%) 4,5-dimethyl-furan-2-carboxylic acid (1-amino-2-benzenesulfonyl-ethylidene)-hydrazide as white crystals with mp. 197-199°C, MS m/e (%): 336 (M+H⁺, 100).

b) 3-Benzenesulfonylmethyl-5-(4,5-dimethyl-furan-2-yl)-1H-[1,2,4]triazole

- 0.92g (0.003mol) 4,5-Dimethyl-furan-2-carboxylic acid (1-amino-2-benzenesulfonyl-ethylidene)-hydrazide were heated at 200°C for 20 minutes. The molten mass was then cooled and purified by chromatography on silicagel with ethylacetate/hexane 7/3 to yield
- 15 0.76g (83%) 3-benzenesulfonylmethyl-5-(4,5-dimethyl-furan-2-yl)-1H-[1,2,4]triazole as white amorphous powder. MS m/e (%): 318 (M+H⁺, 100).

- c) 2-(4,5-Dimethyl-furan-2-yl)-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine, mp. 275-277°C, MS m/e (%): 306 (M+H⁺, 100), was prepared in accordance with the general method of example 1 from 3-benzenesulfonylmethyl-5-(4,5-dimethyl-furan-2-yl)-1H-[1,2,4]triazole and 3-(4-pyridinyl)-2-propenenitrile.
- 20

Example 17

2-Benzofuran-2-yl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

- 25 a) Benzofuran-2-carboxylic acid (1-amino-2-benzenesulfonyl-ethylidene)-hydrazide

- 3.4 g (0.0125 Mol) of 2-(phenylsulfonyl)-ethanimidic acid ethyl ester was stirred together with 2.2 g (0.015mol) benzofuran-2-carboxylic acid hydrazide in 80 ml chloroform for 24 hours at 50°C. The resulting precipitate was filtered off and dried. 2.67 g of benzofuran-2-carboxylic acid (1-amino-2-benzenesulfonyl-ethylidene)-hydrazide was obtained as off-
- 30 white crystals. Mp.: 205-220°C.

b) 3-Benzenesulfonylmethyl-benzofuran-2-yl-1H-[1,2,4]triazole

2.60 g (0.00727mol) Benzofuran-2-carboxylic acid (1-amino-2-benzenesulfonyl-ethylidene)-hydrazide were heated at 210°C for 20 minutes. The molten mass was then cooled, dissolved in 250 ml hot ethanol and stirred overnight at room temperature. The precipitated crystals were filtered off and subjected to column chromatography on SiO₂ with ethyl acetate hexanes 1:1 to yield 2.05 g (83%) 3-benzenesulfonylmethyl-benzofuran-2-yl-1H-[1,2,4]triazole as white crystals, MS (EI) m/e (%): 339 (M⁺, 24).

c) 2-(Benzofuran-2-yl)-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

The title compound was prepared in accordance with the general method of example 1 from 3-benzenesulfonylmethyl-benzofuran-2-yl-1H-[1,2,4]triazole and 3-(4-pyridinyl)-2-propenenitrile. Mp.: 270°C (dec.).

Example 18

7-Pyridin-4-yl-2-thiophen-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

a) Thiophene-2-carboxylic acid N'-(2-benzenesulfonyl-1-imino-ethyl)-hydrazide

A suspension of 13.2g (0.05mol) 2-(phenylsulfonyl)-ethanimidic acid ethyl ester hydrochloride in 110 ml chloroform was treated with 50 ml 1N aqueous sodium hydroxide. 20 ml of a saturated aqueous sodiumbicarbonate solution was added and the mixture was extracted with chloroform. The extracts were combined and dried with sodium sulfate and the solvents were distilled off under reduced pressure. The resulting colorless oil was stirred together with 7.82g (0.05mol) 2-thiophencarboxylic acid hydrazide in 75ml chloroform for 24 hours at 50°C. The resulting precipitate was filtered off and dried. A quantitative yield thiophene-2-carboxylic acid N'-(2-benzenesulfonyl-1-imino-ethyl)-hydrazide was obtained as white crystals. MS m/e (%): 324 (M+H⁺, 100).

b) 3-Benzenesulfonylmethyl-5-thiophen-2-yl-1H-[1,2,4]triazole

1.00g (0.003mol) Thiophene-2-carboxylic acid N'-(2-benzenesulfonyl-1-imino-ethyl)-hydrazide were heated at 200°C for 20 minutes. The molten mass was then cooled, dissolved in 5 ml hot ethanol and stirred for one hour at room temperature. The precipitated crystals were filtered off and dried to yield 0.87 g (93%) 3-benzenesulfonylmethyl-5-thiophen-2-yl-1H-[1,2,4]triazole as yellow crystals with mp. 191-193°C. MS m/e (%): 305 (M⁺, 100).

c) 7-Pyridin-4-yl-2-thiophen-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine, MS m/e (%): 293 (M⁺, 100), was prepared in accordance with the general method of example 1 from 3-benzenesulfonylmethyl-5-thiophen-2-yl-1H-[1,2,4]triazole and 3-pyridin-4-yl-acrylonitrile.

Example 19

2-(5-Methyl-thiophen-2-yl)-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

a) 5-Methyl-thiophen-2-carboxylic acid (1-amino-2-benzenesulfonyl-ethylidene)-hydrazide

- 5 1.75 g (0.0077 Mol) of 2-(phenylsulfonyl)-ethanimidic acid ethyl ester was stirred together with 1.2 g (0.0077mol) 5-methyl-thiophen-2-carboxylic acid hydrazide in 14 ml chloroform for 24 hours at 50°C. The resulting precipitate was filtered off and dried. 2.37 g of 5-methyl-thiophen-2-carboxylic acid (1-amino-2-benzenesulfonyl-ethylidene)-hydrazide was obtained as off-white crystals. Mp.: 222°C (dec.).

- 10 b) 3-Benzenesulfonylmethyl-5-methyl-thiophen-2-yl-1H-[1,2,4]triazole

- 2.33 g (0.0069mol) 5-Methylthiophen-2-carboxylic acid (1-amino-2-benzenesulfonyl-ethylidene)-hydrazide were heated at 210°C for 20 minutes. The molten mass was then cooled, dissolved in 250 ml hot ethanol and stirred overnight at room temperature. The precipitated crystals were filtered off and subjected to column chromatography on silicagel
15 with ethyl acetate hexanes 2:1 to yield 2.05 g (92%) 3-benzenesulfonylmethyl-5-methyl-thiophen-2-yl-1H-[1,2,4]triazole as a yellow foam, MS (EI) m/e (%): 319 (M⁺, 24).

c) 2-(5-Methyl-thiophen-2-yl)-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

- The title compound was prepared in accordance with the general method of example 1 from 3-benzenesulfonylmethyl-5-methyl-thiophen-2-yl-1H-[1,2,4]triazole and 3-(4-
20 pyridinyl)-2-propenenitrile. Mp.: 254-256°C (dec.).

Example 20

N-[2-(5-Methyl-thiophen-2-yl)-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl]-acetamide

- This compound was obtained as a byproduct in the reaction above as a yellow solid. Mp.:
25 226-228°C.

Example 21

2-Pyridin-2-yl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

a) Pyridine-2-carboxylic acid (1-amino-2-benzenesulfonyl-ethylidene)-hydrazide

A suspension of 9.24g (0.035mol) 2-(phenylsulfonyl)-ethanimidic acid ethyl ester hydrochloride in 100 ml chloroform was treated with 35 ml 1N aqueous sodium hydroxide. 14 ml of a saturated aqueous sodiumbicarbonate solution was added and the mixture was extracted with chloroform. The extracts were combined and dried with sodium sulfate and
 5 the solvents were distilled off under reduced pressure. The resulting colorless oil was stirred together with 5.12g (0.037mol) 2-picolinyl hydrazide in 60 ml chloroform for 24 hours at 50°C. The resulting precipitate was filtered off and dried. A quantitative yield of pyridine-2-carboxylic acid (1-amino-2-benzenesulfonyl-ethylidene)-hydrazide was obtained as white crystals. MS m/e (%): 319 (M+H⁺, 100).

10 b) 3-Benzenesulfonylmethyl-5-pyridin-2-yl-1H-[1,2,4]triazole

7.70g (0.025mol) Pyridine-2-carboxylic acid (1-amino-2-benzenesulfonyl-ethylidene)-hydrazide were heated at 200°C for 20 minutes. The molten mass was then cooled, dissolved in 30 ml hot ethanol and stirred for two hours at room temperature. The precipitated crystals were filtered off and dried to yield 6.22 g (84%) 3-benzenesulfonylmethyl-5-pyridin-2-yl-1H-[1,2,4]triazole. MS m/e (%): 300 (M⁺, 100).
 15

c) 2-Pyridin-2-yl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

The 2-pyridin-2-yl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine, MS m/e (%): 289 (M+H⁺, 100), was prepared in accordance with the general method of example 1 from 3-benzenesulfonylmethyl-5-pyridin-2-yl-1H-[1,2,4]triazole and 3-pyridin-4-yl-acrylonitrile.
 20

Example 22

2-Phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

a) Benzenecarboxylic acid (1-amino-2-benzenesulfonyl-ethylidene)-hydrazide

A suspension of 40.0g (0.15mol) 2-(phenylsulfonyl)-ethanimidic acid ethyl ester hydrochloride in 350 ml chloroform was treated with 150 ml 1N aqueous sodium hydroxide. 60 ml of a saturated aqueous sodiumbicarbonate solution was added and the mixture was extracted with chloroform. The extracts were combined and dried with sodium sulfate and the solvents were distilled off under reduced pressure. The resulting colorless oil was stirred together with 22.4g (0.16mol) benzhydrazide in 150 ml chloroform
 25 for 24 hours at 50°C. The solvent was distilled off and the residue was suspended in 150 ml ethanol and stirred for 5 hours at room temperature. Filtration yielded 44.7g (93%) of benzenecarboxylic acid (1-amino-2-benzenesulfonyl-ethylidene)-hydrazide as white crystals with mp. 209-112°C. MS m/e (%): 318 (M+H⁺, 100).
 30

b) 3-Benzenesulfonylmethyl-5-phenyl-1H-[1,2,4]triazole

93.1g (0.29mol) Benzenecarboxylic acid (1-amino-2-benzenesulfonyl-ethylidene)-hydrazide were heated at 200°C for 30 minutes. The molten mass was then cooled, dissolved in 500 ml hot ethanol and stirred for 15 hours at room temperature. The
5 precipitated crystals were filtered off and dried to yield 65.6 g (75%) 3-benzenesulfonylmethyl-5-phenyl-1H-[1,2,4]triazole with mp. 141-144°C. MS m/e (%): 299 (M⁺, 100).

c) 2-Phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine :

To a boiling suspension of 78.8g(0.70mol) potassium tert-butoxide in 400 ml
10 tetrahydrofuran was slowly added over a period of 5 hours a mixture of 70.1g (0.23mol) 3-benzenesulfonylmethyl-5-phenyl-1H-[1,2,4]triazole and 30.5g (0.23mol) 3-(4-pyridinyl)-2-propenenitrile in 800 ml tetrahydrofuran. Boiling was continued for 18 hours and then the mixture was cooled to room temperature. Evaporation of the solvent and
15 chromatography on silicagel with dichloromethane/methanol 95/5 gave 19.8g (29%) 2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine as yellow crystals with mp. 207-210°C, MS m/e (%): 287 (M⁺, 100).

Example 23

2-Phenyl-7-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

The title compound, mp. 278-280°C, MS m/e (%): 288 (M+H⁺, 100), was prepared in
20 accordance with the general method of example 22 from 3-benzenesulfonylmethyl-5-phenyl-1H-[1,2,4]triazole and 3-pyridin-2-yl-acrylonitrile.

Example 24

2-Phenyl-7-pyridin-3-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

The title compound, mp. 201-203°C, MS m/e (%): 288 (M+H⁺, 100), was prepared in
25 accordance with the general method of example 22 from 3-benzenesulfonylmethyl-5-phenyl-1H-[1,2,4]triazole and 3-pyridin-3-yl-acrylonitrile.

Example 25

2,7-Diphenyl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

The title compound, mp. 214-216°C, was prepared in accordance with the general method
30 of example 22 from 3-benzenesulfonylmethyl-5-phenyl-1H-[1,2,4]triazole and cinnamionitrile.

Example 26

5-Amino-2,7-diphenyl-[1,2,4]triazolo[1,5-a]pyridine-8-carbonitril

A solution of 0.18g (0.001mol) 5-phenyl-1H-1,2,4-triazole-3-acetonitrile in 7 ml tetrahydrofuran was treated at -70°C with 1.56ml (0.0025mol) butyllithium (1.6 M in hexane). After one hour 0.21g (0.001mol) 3-bromo-3-phenyl-2-propenenitrile was added, stirring was continued for one hour, the mixture warmed to room temperature over night and water was added. Extraction with diethylether, chromatography on silicagel with dichloromethane/methanol 99/1 and crystallisation from diethylether gave 3.6 mg 5-amino-2,7-diphenyl-[1,2,4]triazolo[1,5-a]pyridine-8-carbonitril as white cystals. MS m/e (%)

10 (%): 312 ($\text{M}+\text{H}^+$, 100).

Example 27

But-3-enyl-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-amine

A solution of 0.20g (0.0007mol) 2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine in 17.5 ml dimethylsulfoxide was treated with 0.69g (0.01mol) potassiumhydroxide(85%) for 20 minutes at room temperature. Then 0.10g(0.0007mol) 4-bromo-1-butene were added and stirring was continued for 40 hours. Saturated aqueous sodiumbicarbonate was added and the mixture was extracted with ethylacetate. Evaporation of the solvent and chromatography on silicagel with dichloromethane/methanol 97/3 gave 0.04g(17%) but-3-enyl-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-amine as beige crystals. MS m/e (%): 341 (M^+ , 21), 300 (100), 287 (65).

15
20

Example 28

Ethyl-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-amine

A solution of 0.29g (0.001mol) 2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine in 50ml dimethylformamide was treated with 0.05g (0.001mol) sodiumhydride(55%) for 15 minutes at room temperature. Then 0.22g (0.001mol) ethyl-p-toluenesulfonate were added and stirring was continued for 22 hours. Saturated aqueous sodiumbicarbonate was added and the mixture was extracted with dichloromethane. Evaporation of the solvent and chromatography on silicagel with dichloromethane/methanol 96/4 gave 0.37g(17%) ethyl-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-amine as beige crystals. MS m/e (%): 316 ($\text{M}+\text{H}^+$, 100).

25
30

Example 29

(2-Phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-carbamic acid ethyl ester

The title compound, MS m/e (%): 360 ($M+H^+$, 100), was prepared in accordance with the general method of example 27 from 2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine and ethyl chloroformate.

Example 30

N-(2-Phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-4-trifluoromethylbenzamide

A mixture of 0.29g (0.001mol) 2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine and 1.13ml(0.014mol) pyridine in 30ml dichloromethane was stirred with 0.63g(0.003mol) p-trifluoromethyl benzoyl chloride for 18 hours at room temperature. Then another 0.63g(0.003mol) p-trifluoromethyl benzoyl chloride were added and stirring was continued at reflux temperature for 48 hours. After extraction with aqueous sodium hydroxide the organic solvents were distilled off and the residue was recrystallised from methanol to yield 0.28g(60%) N-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-4-trifluoromethylbenzamide as white crystals. MS m/e (%): 460 ($M+H^+$, 100).

Example 31

2-(2-Methoxy-phenyl)-N-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-acetamide

A mixture of 0.29g (0.001mol) 2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine and 1.13ml(0.014mol) pyridine in 30ml dichloromethane was stirred with 0.55g(0.003mol) 3-methoxyphenylacetyl chloride for 18 hours at room temperature. After extraction with aqueous sodium hydroxide the organic solvents were distilled off and the residue was purified by chromatography on silicagel with dichloromethane /methanol 98/2 and crystallisation from methanol to yield 0.25g(56%) 2-(2-methoxy-phenyl)-N-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-acetamide as beige crystals. MS m/e (%): 436 ($M+H^+$, 100).

Example 32

2-(2-Chloro-phenyl)-N-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-acetamide

The title compound, MS m/e (%): 440 ($M+H^+$, 100), was prepared in accordance with the general method of example 31 from 2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine and 2-chlorophenylacetyl chloride.

Example 33

- 5 2-(2,4-Dichloro-phenyl)-N-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-acetamide

The title compound, MS m/e (%): 474 ($M+H^+$, 100), was prepared in accordance with the general method of example 31 from 2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine and 2,4-dichlorophenylacetyl chloride.

10

Example 34

2-(3-Chloro-phenyl)-N-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-acetamide

- The title compound, MS m/e (%): 440 ($M+H^+$, 100), was prepared in accordance with the general method of example 31 from 2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine and 3-chlorophenylacetyl chloride.

15

Example 35

2-(3-Fluoro-phenyl)-N-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-acetamide

- The title compound, MS m/e (%): 424 ($M+H^+$, 100), was prepared in accordance with the general method of example 31 from 2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine and 3-fluorophenylacetyl chloride.

20

Example 36

N-(2-Phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-2-(2-trifluoromethyl-phenyl)-acetamide

- 25 The title compound, MS m/e (%): 474 ($M+H^+$, 100), was prepared in accordance with the general method of example 31 from 2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine and 2-(trifluoromethyl)phenylacetyl chloride.

Example 37

N-(2-Phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-2-(3-trifluoromethyl-phenyl)-acetamide

- 5 The title compound, MS m/e (%): 474 ($M+H^+$, 100), was prepared in accordance with the general method of example 31 from 2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine and 3-(trifluoromethyl)phenylacetyl chloride.

Example 38

N-(2-Phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-2-(4-trifluoromethyl-phenyl)-acetamide

- 10 The title compound, MS m/e (%): 474 ($M+H^+$, 100), was prepared in accordance with the general method of example 31 from 2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine and 4-(trifluoromethyl)phenylacetyl chloride.

Example 39

3-Phenyl-N-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-propionamide

- 15 The title compound, MS m/e (%): 420 ($M+H^+$, 100), was prepared in accordance with the general method of example 31 from 2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine and phenylpropionyl chloride.

Example 40

(2-Phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-carbamic acid phenyl ester

- 20 The title compound, MS m/e (%): 408 ($M+H^+$, 100), was prepared in accordance with the general method of example 31 from 2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine and phenyl chloroformate.

Example 41

2-Phenyl-N-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-acetamide

- 25 The title compound, MS m/e (%): 406 ($M+H^+$, 100), was prepared in accordance with the general method of example 31 from 2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine and phenylacetyl chloride.

Example 42

N-(2-Phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-benzamide

The title compound, MS m/e (%): 391 (M^+ , 100), was prepared in accordance with the general method of example 31 from 2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine and benzoylchloride.

Example 43

N-(2-Phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-acetamide

The title compound, MS m/e (%): 330 ($M+H^+$, 100), was prepared in accordance with the general method of example 31 from 2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine and acetylchloride.

Example 44

N-(2-Phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-2-o-tolyl-acetamide

The title compound, MS m/e (%): 420 ($M+H^+$, 100), was prepared in accordance with the general method of example 31 from 2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine and o-tolylacetyl chloride.

Example 45

2-(2-Bromo-phenyl)-N-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-acetamide

The title compound, MS m/e (%): 484,486 ($M+H^+$, 100), was prepared in accordance with the general method of example 31 from 2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine and o-bromophenylacetyl chloride.

Example 46

2-(2-Iodo-phenyl)-N-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-acetamide

The title compound, MS m/e (%): 532 ($M+H^+$, 100), was prepared in accordance with the general method of example 31 from 2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine and o-iodophenylacetyl chloride.

Example 47

3-(2-Phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylcarbamoyl)-propyl]-carbamic acid tert-butyl ester

A solution of 0.82g (0.004mol) Boc-4 aminobutyric acid and 0.66g (0.004mol) 1,1-
5 carbonyl-diimidazole in 70 ml tetrahydrofuran was stirred at room temperature for one hour and was then added at room temperature to a suspension of 0.29g (0.001mol) 2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine and 0.10g (0.002mol) sodiumhydride(55%) in 50 ml dimethylformamide. After stirring at 80°C for 20 hours another 0.10 mg (0.002mol)sodiumhydride(55%) and 0.82g (0.004mol) Boc-4
10 aminobutyric acid were added and stirring was continued for 20 hours at 80°C. The solvent was evaporated, the residue taken up with saturated aqueous sodiumbicarbonate. Extraction with dichloromethane and chromatography on silicagel with dichloromethane/methanol gave 0.02g (5%) [3-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylcarbamoyl)-propyl]-carbamic acid tert-butyl ester. MS
15 m/e (%): 473 (M+H⁺, 100).

Example 48

[2-(2-Methoxy-phenyl)-ethyl]-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-amine

To 10 ml of a 1 molar solution of lithiumborohydride in tetrahydrofuran were added 2.17g
20 (0.02mol) trimethylchlorosilane. After stirring for one hour at room temperature the suspension was added dropwise to a suspension of 0.11g (0.25mol) 2-(2-methoxy-phenyl)-N-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-acetamide and the mixture was heated for 18 hours at 50°C. Then 5 ml methanol were slowly added, the solvents were distilled off and the residue taken up in ethylacetate. The solution was washed with
25 aqueous sodiumhydroxide and with water, dried with sodiumsulfate and evaporated. Recrystallisation from ethanol yielded 0.10g (94%) [2-(2-methoxy-phenyl)-ethyl]-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-amine as beige crystals. MS m/e (%): 422 (M+H⁺, 100).

Example 49

30 (2-Phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-[2-(3-trifluoromethyl-phenyl)-ethyl]-amine

The title compound, MS m/e (%): 460 ($M+H^+$, 100), was prepared in accordance with the general method of example 48 from N-(2-Phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-2-(3-trifluoromethyl-phenyl)-acetamide.

Example 50

- 5 2-(2-Chloro-phenyl)-ethyl]-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-amine

The title compound, MS m/e (%): 426 ($M+H^+$, 100), was prepared in accordance with the general method of example 48 from 2-(2-Chloro-phenyl)-N-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-acetamide.

10

Example 51

2-(2,4-Dichloro-phenyl)-ethyl]-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-amine

- The title compound, MS m/e (%): 460 ($M+H^+$, 100), was prepared in accordance with the general method of example 48 from 2-(2,4-dichloro-phenyl)-N-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-acetamide.

15

Example 52

2-(3-Chloro-phenyl)-ethyl]-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-amine

- The title compound, MS m/e (%): 426 ($M+H^+$, 100), was prepared in accordance with the general method of example 48 from 2-(3-chloro-phenyl)-N-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-acetamide.

20

Example 53

(2-Phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-(4-trifluoromethyl-benzyl)-amine

- 25 The title compound, MS m/e (%): 446($M+H^+$, 100), was prepared in accordance with the general method of example 48 from N-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-4-trifluoromethyl-benzamide.

Example 54

2-(3-Fluoro-phenyl)-ethyl]-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-amine

- The title compound, MS m/e (%): 410 (M+H⁺, 100), was prepared in accordance with the general method of example 48 from 2-(3-fluoro-phenyl)-N-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-acetamide.

Example 55

(2-Phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-[2-(2-trifluoromethyl-phenyl)-ethyl]-amine

- The title compound, MS m/e (%): 460 (M+H⁺, 100), was prepared in accordance with the general method of example 48 from N-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-2-(2-trifluoromethyl-phenyl)-acetamide.

Example 56

- (2-Phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-[2-(4-trifluoromethyl-phenyl)-ethyl]-amine

The title compound, MS m/e (%): 460 (M+H⁺, 100), was prepared in accordance with the general method of example 48 from N-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-2-(4-trifluoromethyl-phenyl)-acetamide.

Example 57

- (3-Phenyl-propyl)-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-amine

The title compound, MS m/e (%): 406 (M+H⁺, 100), was prepared in accordance with the general method of example 48 from 3-phenyl-N-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-propionamide.

Example 58

- Dibenzyl-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-amine

A solution of 0.20g (0.0007mol) 2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine in 17.5 ml dimethylsulfoxide was treated with 0.69g (0.01mol) potassiumhydroxide(85%) for 20 minutes at room temperature. Then 0.26g (0.0015mol) benzylbromide were added and stirring was continued for 70 hours. Saturated aqueous

- sodiumbicarbonate was added and the mixture was extracted with chloroform. Evaporation of the solvent and chromatography on silicagel with dichloromethane/methanol 98/2 and crystallisation from diethylether gave 0.12g (44%) dibenzyl-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-amine as light
- 5 brown crystals. MS m/e (%): 468 (M+H⁺, 100).

Example 59

Diethyl-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-amine

- A solution of 0.29g (0.001mol) 2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine in 50ml dimethylformamide was treated with 0.05g (0.001mol)
- 10 sodiumhydride(55%) for 15 minutes at room temperature. Then 0.22g (0.001mol) ethyl-p-toluenesulfonate were added and stirring was continued for 22 hours. Addition of sodiumhydride and p-toluenesulfonate was repeated three times. After each addition stirring was continued at 50°C for 20 hours. Saturated aqueous sodiumbicarbonate was added and the mixture was extracted with dichloromethane. Evaporation of the solvent
- 15 and chromatography on silicagel with dichloromethane/methanol 96/4 gave 0.05g (15%) diethyl-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-amine as yellow oil. MS m/e (%): 343 (M⁺, 59), 314 (100), 300 (73), 104 (51).

Example 60

- 2-[1-(2-Phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-4,5 dihydro-1H-
- 20 imidazol-2-yl]-benzoic acid

The title compound, MS m/e (%): 461 (M+H⁺, 100), was prepared in accordance with the general method of example 27 from 2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine and N-(2-bromoethyl)-phthalimide.

Example 61

- 25 2-[1-(2-Phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-1,4,5,6-tetrahydro-pyrimidin-2-yl]-benzoic acid

The title compound, MS m/e (%): 475 (M+H⁺, 100), was prepared in accordance with the general method of example 27 from 2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine and N-(3-bromopropyl)-phthalimide.

Example 62

2-[1-(2-Phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-4,5,6,7-tetrahydro-1H-[1,3]diazepin-2-yl]-benzoic acid

The title compound, MS m/e (%): 489 ($M+H^+$, 100), was prepared in accordance with the
5 general method of example 27 from 2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine and N-(4-bromobutyl)-phthalimide.

Example 63

2-Phenyl-7-p-tolyl-3H-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

a) 4-Bromo-pyridine-2,6-dicarboxylic acid diethyl ester

10 A mixture of 4.02g (20mmol) chelidamic acid monohydrate and 34.4g (80mmol) PBr_5 in 60 ml CCl_4 was heated to reflux for 12h and afterwards cautiously treated with 20 ml EtOH. After 30min at 80°C the mixture was cooled to room temperature and the volatile components distilled off under reduced pressure. The remaining residue was treated with 200ml ice/water mixture and stirred for 1h. The white precipitate was filtered off washed
15 with water and dried in high vacuum to yield 5.61g (92.9%) of 4-bromo-pyridine-2,6-dicarboxylic acid diethyl ester, MS m/e (%): 302 ($M+H^+$, 4), 229 ($M^+-(CO_2Et)$, 100)

b) 4-Bromo-pyridine-2,6-dicarboxylic acid dihydrazide

A solution of 4.76g (15.7mmol) 4-bromo-pyridine-2,6-dicarboxylic acid diethyl ester in 87ml ethanol was treated with 18.3 ml of a 24% solution of hydrazine in water and heated
20 to 80°C. The formed white suspension was filtered hot and the collected white precipitate was dried to yield 3.51g (81.4%) of the title compound, MS m/e (%): 276 (M^++2 , 100).

c) 4-Bromo-pyridine-2,6-diamine

A suspension of 1g (3.65mmol) 4-bromo-pyridine-2,6-dicarboxylic acid dihydrazide in 32ml water was treated with 1.6ml HCl (37%) at room temperature. The resulting mixture
25 was cooled to 0°C and 554mg $NaNO_2$ in 2.4ml water was added slowly maintaining the temperature below 2°C. Upon completion saturated $NaHCO_3$ solution was added to pH ~8 and the white precipitate was filtered off and washed with water. The residue was dissolved in $CHCl_3$ and dried with $MgSO_4$. The filtrate was concentrated at 20°C to yield 920mg (85%) of a white solid

30 450mg (1.5mmol) of the white residue were suspended in toluene/t-butanol 5/1. After refluxing for 12h the solvent was removed under reduced pressure and 5ml toluene and

0.3ml trifluoroacetic acid were added and refluxed for 2h. The solvents were removed and the residue was purified by flash chromatography on silica eluting with dichloromethane/methanol 9/1. After removal of the solvents the title compound was liberated through addition of 1N NaOH to a suspension of the residue in diethylether. The organic phase was dried with Na₂SO₄ and the solvents removed under reduced pressure yielding 192mg (67%) of the desired product, MS m/e (%): 188 (M⁺, 100).

d) 7-Bromo-2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

To a solution of 96mg (0.51mmol) 4-bromo-pyridine-2,6-diamine in 2.4ml MeOH was added 121mg (0.56mmol) O-mesitylenesulfonylhydroxylamine (prepared from ethyl o-mesitylenesulfonylacetohydroxamate and HClO₄ (70%)) in 0.6ml MeOH at -5°C and after 15min 71mg (0.56mmol) benzaldehyde and stirred for 30min. The addition of 4.8ml 1N KOH was followed by extraction with ethylacetate, drying of the organic layer with Na₂SO₄, and removal of the volatile components. The residue was purified by column chromatography on silica eluting with ethylacetate and hexane (2:3). 58 mg(39%) of 7-bromo-2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine were isolated, MS m/e (%): 290 (M⁺+2, 44).

e) 2-Phenyl-7-p-tolyl-3H-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

A mixture of 30mg (0.1mmol) 7-bromo-2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine, 15.5mg (0.11mmol) p-tolyl-boronic acid, and 0.1ml aqueous 2M Na₂CO₃ in 0.5ml 1,2-dimethoxyethane was treated with 6mg (0.01mmol) tetrakis-(triphenylphosphine)-palladium(0) and heated to 90°C for 15h. Water was added and the mixture was adjusted to pH=12 with 2M NaOH and extracted with ethylacetate. The organic phases were dried with Na₂SO₄ and concentrated under reduced pressure yielding 22mg (71%) 2-phenyl-7-p-tolyl-3H-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine, MS m/e (%): 300 (M⁺, 100).

Example 64

7-Bromo-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

The title compound, MS m/e (%): 281 (M⁺+2, 100), was prepared in accordance with the general method of example 63 from 4-bromo-pyridine-2,6-diamine, O-mesitylene-sulfonylhydroxylamine, and furfural. The purification was performed with reversed phase HPLC eluting with an acetonitrile/water gradient.

Example 65

7-Bromo-2-(5-methyl-furan-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

The title compound, MS m/e (%): 295 ($M^+ + 2$, 100), was prepared in accordance with the general method of example 63 from 4-bromo-pyridine-2,6-diamine, O-mesitylene-sulfonylhydroxylamine, and 5-methyl-furfural. The purification was performed with reversed phase HPLC eluting with an acetonitrile/water gradient.

5

Example 66

[5-(5-Amino-7-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl)-furan-2-yl]-methanol

The title compound, MS m/e (%): 311 ($M^+ + 2$, 100), was prepared in accordance with the general method of example 63 from 4-bromo-pyridine-2,6-diamine, O-mesitylene-sulfonylhydroxylamine, and 5-hydroxymethyl-furfural. The purification was performed with reversed phase HPLC eluting with an acetonitrile/water gradient.

10

Example 67

7-Bromo-2-(5-bromo-furan-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

The title compound, MS m/e (%): 359 ($M^+ + 1$, 100), was prepared in accordance with the general method of example 63 from 4-bromo-pyridine-2,6-diamine, O-mesitylene-sulfonylhydroxylamine, and 5-bromo-furfural. The purification was performed with reversed phase HPLC eluting with an acetonitrile/water gradient.

15

Example 68

7-Bromo-2-(4-bromo-furan-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

The title compound, MS m/e (%): 359 ($M^+ + 1$, 100), was prepared in accordance with the general method of example 63 from 4-bromo-pyridine-2,6-diamine, O-mesitylene-sulfonylhydroxylamine, and 4-bromo-furfural. The purification was performed with reversed phase HPLC eluting with an acetonitrile/water gradient.

20

Example 69

7-Bromo-2-(2-furan-2-yl-vinyl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

The title compound, MS m/e (%): 305 (M^+ , 100), was prepared in accordance with the general method of example 63 from 4-bromo-pyridine-2,6-diamine, O-mesitylene-sulfonylhydroxylamine, and 3-(2-furyl)-acrolein. The purification was performed with reversed phase HPLC eluting with an acetonitrile/water gradient.

25

Example 70

7-Bromo-2-thiophen-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

The title compound, MS m/e (%): 297 ($M^+ + 2$, 100), was prepared in accordance with the general method of example 63 from 4-bromo-pyridine-2,6-diamine, O-mesitylene-sulfonylhydroxylamine, and 2-thiophenecarboxaldehyde. The purification was performed with reversed phase HPLC eluting with an acetonitrile/water gradient.

Example 71

7-Bromo-2-(3-methyl-thiophen-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

The title compound, MS m/e (%): 309 (M^+ , 100), was prepared in accordance with the general method of example 63 from 4-bromo-pyridine-2,6-diamine, O-mesitylene-sulfonylhydroxylamine, and 3-methylthiophene-2-carboxaldehyde. The purification was performed with reversed phase HPLC eluting with an acetonitrile/water gradient.

Example 72

7-Bromo-2-(4-bromo-thiophen-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

The title compound, MS m/e (%): 375 ($M^+ + 1$, 100), was prepared in accordance with the general method of example 63 from 4-bromo-pyridine-2,6-diamine, O-mesitylene-sulfonylhydroxylamine, and 4-bromothiophene-2-carboxaldehyde. The purification was performed with reversed phase HPLC eluting with an acetonitrile/water gradient.

Example 73

7-Bromo-2-(1-methyl-1H-pyrrol-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

The title compound, MS m/e (%): 294 ($M^+ + 2$, 100), was prepared in accordance with the general method of example 63 from 4-bromo-pyridine-2,6-diamine, O-mesitylene-sulfonylhydroxylamine, and 1-methylpyrrole-2-carboxaldehyde. The purification was performed with reversed phase HPLC eluting with an acetonitrile/water gradient.

Example 74

7-Bromo-2-thiazol-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

The title compound, MS m/e (%): 298 ($M^+ + 2$, 100), was prepared in accordance with the general method of example 63 from 4-bromo-pyridine-2,6-diamine, O-mesitylene-

sulfonylhydroxylamine, and 2-formylthiazole. The purification was performed with reversed phase HPLC eluting with an acetonitrile/water gradient.

Example 75

7-Bromo-2-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

- 5 The title compound, MS m/e (%): 292 ($M^+ + 2$, 100), was prepared in accordance with the general method of example 63 from 4-bromo-pyridine-2,6-diamine, O-mesitylene-sulfonylhydroxylamine, and 4-pyridinecarboxaldehyde. The purification was performed with reversed phase HPLC eluting with an acetonitrile/water gradient.

Example 76

- 10 7-Bromo-2-(6-methyl-pyridin-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

The title compound, MS m/e (%): 306 ($M^+ + 2$, 100), was prepared in accordance with the general method of example 63 from 4-bromo-pyridine-2,6-diamine, O-mesitylene-sulfonylhydroxylamine, and 6-methylpyridine-2-aldehyde. The purification was performed with reversed phase HPLC eluting with an acetonitrile/water gradient.

15

Example 77

7-Bromo-2-(1H-indol-3-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

- The title compound, MS m/e (%): 328 (M^+ , 100), was prepared in accordance with the general method of example 63 from 4-bromo-pyridine-2,6-diamine, O-mesitylene-sulfonylhydroxylamine, and indole-3-carboxaldehyde. The purification was performed
20 with reversed phase HPLC eluting with an acetonitrile/water gradient.

Example 78

2-(5-Amino-7-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl)-phenol

- The title compound, MS m/e (%): 307 ($M^+ + 2$, 100), was prepared in accordance with the general method of example 63 from 4-bromo-pyridine-2,6-diamine, O-mesitylene-sulfonylhydroxylamine, and salicylaldehyde. The purification was performed with reversed
25 phase HPLC eluting with an acetonitrile/water gradient.

Example 79

7-Bromo-2-(2-methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

The title compound, MS m/e (%): 321 ($M^+ + 2$, 100), was prepared in accordance with the general method of example 63 from 4-bromo-pyridine-2,6-diamine, O-mesitylene-sulfonylhydroxylamine, and o-anisaldehyde. The purification was performed with reversed phase HPLC eluting with an acetonitrile/water gradient.

5

Example 80

7-Bromo-2-(5-ethyl-furan-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

The title compound, MS m/e (%): 309 ($M^+ + 2$, 100), was prepared in accordance with the general method of example 63 from 4-bromo-pyridine-2,6-diamine, O-mesitylene-sulfonylhydroxylamine, and 5-ethyl-2-furaldehyde. The purification was performed with reversed phase HPLC eluting with an acetonitrile/water gradient.

10

Example 81

7-Bromo-2-furan-3-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

The title compound, MS m/e (%): 281 ($M^+ + 2$, 100), was prepared in accordance with the general method of example 63 from 4-bromo-pyridine-2,6-diamine, O-mesitylene-sulfonylhydroxylamine, and 3-furaldehyde. The purification was performed with reversed phase HPLC eluting with an acetonitrile/water gradient.

15

Example 82

7-Bromo-2-(5-methyl-thiophen-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

The title compound, MS m/e (%): 311 ($M^+ + 2$, 100), was prepared in accordance with the general method of example 63 from 4-bromo-pyridine-2,6-diamine, O-mesitylene-sulfonylhydroxylamine, and 5-methyl-2-thiophenecarboxaldehyde. The purification was performed with reversed phase HPLC eluting with an acetonitrile/water gradient.

20

Example 83

7-Bromo-2-(tetrahydro-furan-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

The title compound, MS m/e (%): 283 (M^+ , 100), was prepared in accordance with the general method of example 63 from 4-bromo-pyridine-2,6-diamine, O-mesitylene-sulfonylhydroxylamine, and tetrahydro-furan-2-carbaldehyde. The purification was performed with reversed phase HPLC eluting with an acetonitrile/water gradient.

25

Example 84

7-Bromo-2-(3-fluoro-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

The title compound, MS m/e (%): 307 (M^+ , 100), was prepared in accordance with the general method of example 63 from 4-bromo-pyridine-2,6-diamine, O-mesitylene-sulfonylhydroxylamine, and 3-fluoro-benzaldehyde. The purification was performed with reversed phase HPLC eluting with an acetonitrile/water gradient.

Example 85

7-Bromo-2-(5-methoxy-thiophen-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

The title compound, MS m/e (%): 325 (M^+ , 100), was prepared in accordance with the general method of example 63 from 4-bromo-pyridine-2,6-diamine, O-mesitylene-sulfonylhydroxylamine, and 5-methoxy-thiophene-2-carbaldehyde. The purification was performed with reversed phase HPLC eluting with an acetonitrile/water gradient.

Example 86

7-Bromo-2-(4-methoxy-thiophen-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

The title compound, MS m/e (%): 325 (M^+ , 100), was prepared in accordance with the general method of example 63 from 4-bromo-pyridine-2,6-diamine, O-mesitylene-sulfonylhydroxylamine, and 4-methoxy-thiophene-2-carbaldehyde. The purification was performed with reversed phase HPLC eluting with an acetonitrile/water gradient.

Example 87

7-Bromo-2-(5,6-dihydro-4H-pyran-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

The title compound, MS m/e (%): 295 (M^+ , 100), was prepared in accordance with the general method of example 63 from 4-bromo-pyridine-2,6-diamine, O-mesitylene-sulfonylhydroxylamine, and 5,6-dihydro-4H-pyran-2-carbaldehyde. The purification was performed with reversed phase HPLC eluting with an acetonitrile/water gradient.

Example 88

7-Bromo-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

The title compound, MS m/e (%): 290 (M^+ , 100), was prepared in accordance with the general method of example 63 from 4-bromo-pyridine-2,6-diamine, O-mesitylene-

sulfonylhydroxylamine, and pyridine-2-carbaldehyde. The purification was performed with reversed phase HPLC eluting with an acetonitrile/water gradient.

Example 89

7-Bromo-2-(2-fluoro-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

- 5 The title compound, MS m/e (%): 290 (M^+ , 100), was prepared in accordance with the general method of example 63 from 4-bromo-pyridine-2,6-diamine, O-mesitylene-sulfonylhydroxylamine, and 2-fluoro-benzaldehyde. The purification was performed with reversed phase HPLC eluting with an acetonitrile/water gradient.

Example 90

- 10 7-Bromo-2-(6-methoxy-pyridin-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

The title compound, MS m/e (%): 320 (M^+ , 100), was prepared in accordance with the general method of example 63 from 4-bromo-pyridine-2,6-diamine, O-mesitylene-sulfonylhydroxylamine, and 6-methoxy-pyridine-2-carbaldehyde. The purification was performed with reversed phase HPLC eluting with an acetonitrile/water gradient.

- 15

Example 91

7-Bromo-2-isoxazol-5-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine







- The title compound, MS m/e (%): 280 (M^+ , 100), was prepared in accordance with the general method of example 63 from 4-bromo-pyridine-2,6-diamine, O-mesitylene-sulfonylhydroxylamine, and isoxazole-5-carbaldehyde. The purification was performed with reversed phase HPLC eluting with an acetonitrile/water gradient.
- 20







Example 92








7-(4-Methoxy-phenyl)-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

- A mixture of 72.5 mg (0.25mmol) 7-bromo-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine, 37.4 mg (0.275mmol) p-methoxy-boronic acid, and 0.22 ml 2M Na_2CO_3 in 0.78 ml dioxane was treated with 0.05 eq. dichloro (1,1'-bis(diphenylphosphino)ferrocene)palladium (II) dichloromethane adduct and heated to 100°C for 15 h. Formic acid was added and the mixture was purified by reversed phase column chromatography eluting with an acetonitrile/water gradient yielding 13.3 mg (17%) of the title compound. MS m/e (%): 318 ($M+H^+$, 100)
- 25








According to example 63 or example 92 triazolopyridine derivatives have been synthesised. The results are compiled in the following list comprising example 93 to example 220







Example No.	Structure	name	MS m/e (%)	MW	Syntesis according to example No.
93		7-(3-Amino-phenyl)-2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	301.4	63
94		7-(3-Fluoro-phenyl)-2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	304.3	63
95		7-(4-Methoxy-phenyl)-2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	316.4	63
96		7-(3-Chloro-4-fluoro-phenyl)-2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	338.8	63
97		7-(3-Ethoxy-phenyl)-2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	330.4	63
98		7-(3-Methoxy-phenyl)-2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	316.4	63

Example No.	Structure	name	MS m/e (%)	MW	Synthesis according to example No.
99		N-[3-(5-Amino-2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-phenyl]-acetamide	M+H ⁺ (100)	343.4	63
100		7-Benzo[1,3]dioxol-5-yl-2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	330.3	63
101		7-(1H-Indol-5-yl)-2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	325.4	63
102		3-(5-Amino-2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-benzonitrile	M+H ⁺ (100)	311.3	63
103		N-[4-(5-Amino-2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methyl-phenyl]-acetamide	M+H ⁺ (100)	357.4	63
104		7-(3-Amino-phenyl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	291.3	63

Example No.	Structure	name	MS m/e (%)	MW	Syntesis according to example No.
105		7-(3,4-Dimethoxy-phenyl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	336.4	63
106		7-(3,4-Dichloro-phenyl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M ⁺ (100)	345.2	63
107		7-(3-Fluoro-phenyl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	294.3	63
108		7-(2,6-Difluoro-phenyl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	312.3	63
109		7-(2,4-Dimethoxy-phenyl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	336.4	63
110		1-[3-(5-Amino-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-phenyl]-ethanone	M+H ⁺ (100)	318.3	63
111		7-(2-Fluoro-phenyl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	294.3	63







Example No.	Structure	name	MS m/e (%)	MW	Syntesis according to example No.
112		2-Furan-2-yl-7-naphthalen-1-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	326.4	63
113		2-Furan-2-yl-7-(4-trifluoromethyl-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	344.3	63
114		7-(3-Chloro-phenyl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	310.7	63
115		7-Benzofuran-2-yl-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	316.3	63
116		7-(2-Chloro-phenyl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	310.7	63
117		2-Furan-2-yl-7-(4-methylsulfanyl-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	322.4	63
118		2-Furan-2-yl-7-m-tolyl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	290.3	63








Example No.	Structure	name	MS m/e (%)	MW	Syntesis according to example No.
119		2-Furan-2-yl-7-o-tolyl- [1,2,4]triazolo[1,5- a]pyridin-5-ylamine	M+H ⁺ (100)	290.3	63
120		2-Furan-2-yl-7- thiophen-3-yl- [1,2,4]triazolo[1,5- a]pyridin-5-ylamine	M+H ⁺ (100)	282.3	63
121		2-Furan-2-yl-7- thiophen-2-yl- [1,2,4]triazolo[1,5- a]pyridin-5-ylamine	M+H ⁺ (100)	282.3	63
122		2-Furan-2-yl-7-(3- trifluoromethyl-phenyl)- [1,2,4]triazolo[1,5- a]pyridin-5-ylamine	M+H ⁺ (100)	344.3	63
123		2-Furan-2-yl-7-(2- methoxy-phenyl)- [1,2,4]triazolo[1,5- a]pyridin-5-ylamine	M+H ⁺ (100)	306.3	63
124		2-Furan-2-yl-7-(4- methoxy-phenyl)- [1,2,4]triazolo[1,5- a]pyridin-5-ylamine	M+H ⁺ (100)	306.3	63
125		7-(3-Ethoxy-phenyl)-2- furan-2-yl- [1,2,4]triazolo[1,5- a]pyridin-5-ylamine	M+H ⁺ (100)	320.4	63








Example No.	Structure	name	MS m/e (%)	MW	Synthesis according to example No.
126		2-Furan-2-yl-7-(3-methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	306.3	63
127		N-[3-(5-Amino-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-phenyl]-acetamide	M+H ⁺ (100)	333.4	63
128		2-Furan-2-yl-7-(4-trifluoromethoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	360.3	63
129		7-Benzo[1,3]dioxol-5-yl-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	320.3	63
130		2-Furan-2-yl-7-(1H-indol-5-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	315.3	63
131		3-(5-Amino-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-benzonitrile	M+H ⁺ (100)	301.3	63

Example No.	Structure	name	MS m/e (%)	MW	Synthesis according to example No.
132		N-[4-(5-Amino-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methyl-phenyl]-acetamide	M+H ⁺ (100)	347.4	63
133		7-(4-Dimethylamino-phenyl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	319.4	63
134		2-(5-Methyl-furan-2-yl)-7-phenyl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	290.3	63
135		2-(5-Methyl-furan-2-yl)-7-o-tolyl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	304.4	63
136		2-(5-Methyl-furan-2-yl)-7-m-tolyl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	304.4	63
137		2-(5-Methyl-furan-2-yl)-7-p-tolyl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	304.4	63
138		7-(2-Fluoro-phenyl)-2-(5-methyl-furan-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	308.3	63

Example No.	Structure	name	MS m/e (%)	MW	Synthesis according to example No.
139		7-(3-Fluoro-phenyl)-2-(5-methyl-furan-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	308.3	63
140		7-(2-Chloro-phenyl)-2-(5-methyl-furan-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M ⁺ (100)	324.8	63
141		7-(3-Chloro-phenyl)-2-(5-methyl-furan-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M ⁺ (100)	324.8	63
142		7-(4-Chloro-phenyl)-2-(5-methyl-furan-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M ⁺ (100)	324.8	63
143		2-(5-Methyl-furan-2-yl)-7-(3-trifluoromethyl-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	358.3	63
144		2-(5-Methyl-furan-2-yl)-7-(4-trifluoromethyl-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	358.3	63







Example No.	Structure	name	MS m/e (%)	MW	Syntesis according to example No.
145		7-(2-Methoxy-phenyl)-2-(5-methyl-furan-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	320.4	63
146		7-(3-Methoxy-phenyl)-2-(5-methyl-furan-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	320.4	63
147		7-(4-Methoxy-phenyl)-2-(5-methyl-furan-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	320.4	63
148		7-(3,4-Dimethoxy-phenyl)-2-(5-methyl-furan-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	350.4	63
149		7-(2,4-Dimethoxy-phenyl)-2-(5-methyl-furan-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	350.4	63
150		N-{3-[5-Amino-2-(5-methyl-furan-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-7-yl]-phenyl}-acetamide	M+H ⁺ (100)	347.4	63








Example No.	Structure	name	MS m/e (%)	MW	Syntesis according to example No.
151		N-{4-[5-Amino-2-(5-methyl-furan-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-7-yl]-phenyl}-acetamide	M+H ⁺ (100)	347.4	63
152		7-(4-Dimethylamino-phenyl)-2-(5-methyl-furan-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	333.4	63
153		7-Phenyl-2-thiophen-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	292.4	63
154		2-Thiophen-2-yl-7-m-tolyl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	306.4	63
155		2-Thiophen-2-yl-7-p-tolyl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	306.4	63
156		7-(2-Fluoro-phenyl)-2-thiophen-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	310.4	63
157		2-Thiophen-2-yl-7-(3-trifluoromethyl-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	360.4	63

Example No.	Structure	name	MS m/e (%)	MW	Syntesis according to example No.
158		7-(3-Methoxy-phenyl)-2-thiophen-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	322.4	63
159		N-[3-(5-Amino-2-thiophen-2-yl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-phenyl]-acetamide	M+H ⁺ (100)	349.4	63
160		7-(3-Amino-phenyl)-2-thiophen-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	307.4	63
161		7-(4-Dimethylamino-phenyl)-2-thiophen-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	335.4	63
162		2-Pyridin-2-yl-7-o-tolyl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	301.4	92
163		2-Pyridin-2-yl-7-m-tolyl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	301.4	92
164		2-Pyridin-2-yl-7-p-tolyl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	301.4	92

Example No.	Structure	name	MS m/e (%)	MW	Syntesis according to example No.
165		7-(2-Fluoro-phenyl)-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	305.3	92
166		7-(3-Fluoro-phenyl)-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	305.3	92
167		7-(4-Fluoro-phenyl)-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	305.3	92
168		7-(3-Chloro-4-fluoro-phenyl)-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M ⁺ (100)	339.8	92
169		7-(2-Chloro-phenyl)-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M ⁺ (100)	321.8	92
170		7-(3-Chloro-phenyl)-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M ⁺ (100)	321.8	92
171		7-(4-Chloro-phenyl)-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M ⁺ (100)	321.8	92







Example No.	Structure	name	MS m/e (%)	MW	Syntesis according to example No.
172		7-(3,4-Dichloro-phenyl)- 2-pyridin-2-yl- [1,2,4]triazolo[1,5- a]pyridin-5-ylamine	M ⁺ (100)	356.2	92
173		2-Pyridin-2-yl-7-(3- trifluoromethyl-phenyl)- [1,2,4]triazolo[1,5- a]pyridin-5-ylamine	M+H ⁺ (100)	355.3	92
174		2-Pyridin-2-yl-7-(4- trifluoromethyl-phenyl)- [1,2,4]triazolo[1,5- a]pyridin-5-ylamine	M+H ⁺ (100)	355.3	92
175		7-(2-Methoxy-phenyl)-2- pyridin-2-yl- [1,2,4]triazolo[1,5- a]pyridin-5-ylamine	M+H ⁺ (100)	317.4	92
176		7-(3-Methoxy-phenyl)-2- pyridin-2-yl- [1,2,4]triazolo[1,5- a]pyridin-5-ylamine	M+H ⁺ (100)	317.4	92
177		7-(3,4-Dimethoxy- phenyl)-2-pyridin-2-yl- [1,2,4]triazolo[1,5- a]pyridin-5-ylamine	M+H ⁺ (100)	347.4	92
178		7-(2,4-Dimethoxy- phenyl)-2-pyridin-2-yl- [1,2,4]triazolo[1,5- a]pyridin-5-ylamine	M+H ⁺ (100)	347.4	92







Example No.	Structure	name	MS m/e (%)	MW	Syntesis according to example No.
179		N-[3-(5-Amino-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-phenyl]-acetamide	M+H ⁺ (100)	344.4	92
180		N-[4-(5-Amino-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-phenyl]-acetamide	M+H ⁺ (100)	344.4	92
181		7-(3-Amino-phenyl)-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	302.3	92
182		2-Isoxazol-5-yl-7-phenyl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	277.3	92
183		7-(2-Fluoro-phenyl)-2-isoxazol-5-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	295.3	92
184		7-(3-Fluoro-phenyl)-2-isoxazol-5-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	295.3	92

Example No.	Structure	name	MS m/e (%)	MW	Synthesis according to example No.
185		7-(4-Fluoro-phenyl)-2-isoxazol-5-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	295.3	92
186		7-(3-Chloro-4-fluoro-phenyl)-2-isoxazol-5-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M ⁺ (100)	329.7	92
187		7-(3-Chloro-phenyl)-2-isoxazol-5-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M ⁺ (100)	311.7	92
188		7-(3,4-Dichloro-phenyl)-2-isoxazol-5-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M ⁺ (100)	346.2	92
189		2-Isoxazol-5-yl-7-(3-methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	307.3	92
190		2-Isoxazol-5-yl-7-(4-methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	307.3	92
191		7-(3,4-Dimethoxy-phenyl)-2-isoxazol-5-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	337.3	92

Example No.	Structure	name	MS m/e (%)	MW	Syntesis according to example No.
192		7-(2,4-Dimethoxyphenyl)-2-isoxazol-5-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	337.3	92
193		2-Isoxazol-5-yl-7-m-tolyl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	291.3	92
194		2-Isoxazol-5-yl-7-p-tolyl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	291.3	92
195		7-(3-Amino-phenyl)-2-isoxazol-5-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	292.3	92
196		N-[3-(5-Amino-2-isoxazol-5-yl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-phenyl]-acetamide	M+H ⁺ (100)	334.3	92
197		7-(3,4-Dichloro-phenyl)-2-(4,5-dihydro-furan-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M ⁺ (100)	347.2	92
198		2-(4,5-Dihydro-furan-2-yl)-7-(3-fluoro-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	296.3	92

Example No.	Structure	name	MS m/e (%)	MW	Syntesis according to example No.
199		2-(4,5-Dihydro-furan-2-yl)-7-(4-fluoro-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	296.3	92
200		2-(4,5-Dihydro-furan-2-yl)-7-m-tolyl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	292.3	92
201		2-(4,5-Dihydro-furan-2-yl)-7-(3-trifluoromethyl-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	346.3	92
202		N-{4-[5-Amino-2-(4,5-dihydro-furan-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-7-yl]-phenyl}-acetamide	M+H ⁺ (100)	335.4	92
203		2-(6-Methoxy-pyridin-2-yl)-7-phenyl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	317.4	92
204		2-(5-Methoxy-thiophen-2-yl)-7-phenyl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	322.4	92

Example No.	Structure	name	MS m/e (%)	MW	Syntesis according to example No.
205		2-(4-Methoxy-thiophen-2-yl)-7-phenyl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	322.4	92
206		7-(3-Fluoro-phenyl)-2-(4-methoxy-thiophen-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	340.4	92
207		7-(4-Fluoro-phenyl)-2-(4-methoxy-thiophen-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	340.4	92
208		7-(4-Chloro-phenyl)-2-(4-methoxy-thiophen-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M ⁺ (100)	356.8	92
209		7-(4-Methoxy-phenyl)-2-(4-methoxy-thiophen-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	352.4	92
210		N-{3-[5-Amino-2-(4-methoxy-thiophen-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-7-yl]-phenyl}-acetamide	M+H ⁺ (100)	379.4	92

Example No.	Structure	name	MS m/e (%)	MW	Syntesis according to example No.
211		N-{4-[5-Amino-2-(4-methoxy-thiophen-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-7-yl]-phenyl}-acetamide	M+H ⁺ (100)	379.4	92
212		2-(5,6-Dihydro-4H-pyran-2-yl)-7-(2-fluorophenyl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	310.3	92
213		2-(5,6-Dihydro-4H-pyran-2-yl)-7-(3-fluorophenyl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	310.3	92
214		2-(5,6-Dihydro-4H-pyran-2-yl)-7-(4-fluorophenyl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	310.3	92
215		7-(3-Chloro-4-fluorophenyl)-2-(5,6-dihydro-4H-pyran-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M ⁺ (100)	344.8	92
216		7-(3-Chlorophenyl)-2-(5,6-dihydro-4H-pyran-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M ⁺ (100)	326.8	92

Example No.	Structure	name	MS m/e (%)	MW	Syntesis according to example No.
217		7-(4-Chloro-phenyl)-2-(5,6-dihydro-4H-pyran-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M ⁺ (100)	326.8	92
218		2-(5,6-Dihydro-4H-pyran-2-yl)-7-m-tolyl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	306.4	92
219		2-(5,6-Dihydro-4H-pyran-2-yl)-7-p-tolyl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	306.4	92
220		2-(5,6-Dihydro-4H-pyran-2-yl)-7-(3-trifluoromethyl-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	360.3	92

Example 221

7-Morpholin-4-yl-2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine (RO-69-0728/000)

A mixture of 40mg (0.138 mmol) 7-bromo-2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine, 241 ul (2.8mmol) morpholin and 225mg (0.69mmol) Cs₂CO₃ in 200ul DMF was heated 20h to 140°C. Filtration and subsequent purification with reversed phase column chromatography eluting with an acetonitrile/water gradient yielded 20mg (49%) of the title compound, MS m/e (%): 296 M+H⁺ (100%).

According to example 221 triazolopyridine derivatives have been synthesised through the reaction of the appropriate bromide substituted triazolo-pyridine with the respective amine and subsequently isolated with reversed phase column chromatography eluting with an acetonitrile/water gradient. The results are compiled in the following list comprising



example 222 to example 255. For some examples N-methyl-pyrrolidon (NMP) at 160°C was used instead of DMF at 140°. This is indicated in the following list with the additional comment "NMP" respectively "DMF".

Example No.	structure	name	MS m/e (%)	MW	condition
222		N7-Indan-1-yl-2-phenyl-[1,2,4]triazolo[1,5-a]pyridine-5,7-diamine	M+H ⁺ (100)	341.4	NMP
223		2-Phenyl-N7-(1,2,3,4-tetrahydro-naphthalen-1-yl)-[1,2,4]triazolo[1,5-a]pyridine-5,7-diamine	M+H ⁺ (100)	355.4	NMP
224		N7-(3-Chloro-benzyl)-2-phenyl-[1,2,4]triazolo[1,5-a]pyridine-5,7-diamine	M ⁺ (100)	349.8	NMP
225		2-Phenyl-N7-(1-phenyl-ethyl)-[1,2,4]triazolo[1,5-a]pyridine-5,7-diamine	M+H ⁺ (100)	329.4	NMP
226		N7-Cyclohexyl-N7-ethyl-2-phenyl-[1,2,4]triazolo[1,5-a]pyridine-5,7-diamine	M+H ⁺ (100)	335.5	NMP
227		2-Phenyl-7-(1,3,4,9-tetrahydro-b-carbolin-2-yl)-[1,2,4]triazolo[1,5-a]pyridine-5-ylamine	M+H ⁺ (100)	380.5	NMP
228		2-Phenyl-7-piperidin-1-yl-[1,2,4]triazolo[1,5-a]pyridine-5-ylamine	M+H ⁺ (100)	293.4	NMP

Example No.	structure	name	MS m/e (%)	MW	condition
229		2-Phenyl-7-pyrrolidin-1-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	279.3	NMP
230		2-Furan-2-yl-7-piperidin-1-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	283.3	NMP
231		2-Furan-2-yl-7-pyrrolidin-1-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	269.3	NMP
232		2-Furan-2-yl-7-(4-methylpiperazin-1-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	M+H ⁺ (100)	298.4	NMP
233		2-Furan-2-yl-N7-indan-1-yl-[1,2,4]triazolo[1,5-a]pyridine-5,7-diamine	M+H ⁺ (100)	331.4	NMP
234		2-Furan-2-yl-N7-(4-methoxybenzyl)-[1,2,4]triazolo[1,5-a]pyridine-5,7-diamine	M+H ⁺ (100)	335.4	NMP
235		N7-(2,4-Dimethoxy-benzyl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridine-5,7-diamine	M+H ⁺ (100)	365.4	NMP
236		2-Furan-2-yl-N7-(1,2,3,4-tetrahydro-naphthalen-1-yl)-[1,2,4]triazolo[1,5-a]pyridine-5,7-diamine	M+H ⁺ (100)	345.4	NMP

Example No.	structure	name	MS m/e (%)	MW	condition
237		N7-(4-Chloro-benzyl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridine-5,7-diamine	M ⁺ (100)	339.8	NMP
238		N7-(2-Chloro-benzyl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridine-5,7-diamine	M ⁺ (100)	339.8	NMP
239		N7-(3,4-Dimethoxy-benzyl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridine-5,7-diamine	M+H ⁺ (100)	365.4	NMP
240		2-Furan-2-yl-N7-(2-methoxy-benzyl)-[1,2,4]triazolo[1,5-a]pyridine-5,7-diamine	M+H ⁺ (100)	335.4	NMP
241		2-Furan-2-yl-N7-(1-phenyl-ethyl)-[1,2,4]triazolo[1,5-a]pyridine-5,7-diamine	M+H ⁺ (100)	319.4	NMP
242		N7-Cyclohexyl-N7-ethyl-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridine-5,7-diamine	M+H ⁺ (100)	325.4	NMP
243		2-Furan-2-yl-7-(1,3,4,9-tetrahydro-b-carbolin-2-yl)-[1,2,4]triazolo[1,5-a]pyridine-5-ylamine	M+H ⁺ (100)	370.4	NMP
244		N7-Benzyl-2-furan-2-yl-N7-phenyl-[1,2,4]triazolo[1,5-a]pyridine-5,7-diamine	M+H ⁺ (100)	381.4	NMP
245		N7-Benzyl-N7-methyl-2-phenyl-[1,2,4]triazolo[1,5-a]pyridine-5,7-diamine	M+H ⁺ (100)	329.4	DMF

Example No.	structure	name	MS m/e (%)	MW	condition
246		N7-Benzyl-2-phenyl-[1,2,4]triazolo[1,5-a]pyridine-5,7-diamine	M+H ⁺ (100)	315.4	DMF
247		N7-Benzyl-2-(3-fluoro-phenyl)-[1,2,4]triazolo[1,5-a]pyridine-5,7-diamine	M+H ⁺ (100)	333.4	NMP
248		N7-Cyclohexyl-N7-ethyl-2-(3-fluoro-phenyl)-[1,2,4]triazolo[1,5-a]pyridine-5,7-diamine	M+H ⁺ (100)	353.4	NMP
249		N7-Benzyl-2-(2-fluoro-phenyl)-[1,2,4]triazolo[1,5-a]pyridine-5,7-diamine	M+H ⁺ (100)	333.4	NMP
250		N7-(2-Chloro-benzyl)-2-(3-fluoro-phenyl)-[1,2,4]triazolo[1,5-a]pyridine-5,7-diamine	M ⁺ (100)	367.8	NMP
251		N7-(2-Chloro-benzyl)-2-(2-fluoro-phenyl)-[1,2,4]triazolo[1,5-a]pyridine-5,7-diamine	M ⁺ (100)	367.8	NMP
252		7-Piperidin-1-yl-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridine-5-ylamine	M+H ⁺ (100)	294.4	NMP
253		N7-(2-Chloro-benzyl)-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridine-5,7-diamine	M ⁺ (100)	350.8	NMP

Example No.	structure	name	MS m/e (%)	MW	condition
254		N7-(2-Methoxy-benzyl)-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridine-5,7-diamine	M+H ⁺ (100)	346.4	NMP
255		N7-Benzyl-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridine-5,7-diamine	M+H ⁺ (100)	316.4	NMP

Example 256

2-Furan-2-yl-7-(4-methoxy-phenoxy)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

A mixture of 1eq. 7-bromo-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine, 5eq. p-methoxy-phenol and a catalytic amount of Cs₂CO₃ in 200μl N-methyl-pyrrolidone was heated for 2h to 160°. The mixture was, after filtration, purified with reversed phase column chromatography eluting with an acetonitrile/water gradient yielding the title compound, MS m/e (%): 322 M+H⁺ (100%).

Example 257

7-(4-Bromo-phenoxy)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

A mixture of 1eq. 7-bromo-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine, 5eq. p-bromo-phenol and a catalytic amount of Cs₂CO₃ in 200μl N-methyl-pyrrolidone was heated for 2h to 160°. The mixture was, after filtration, purified with reversed phase column chromatography eluting with an acetonitrile/water gradient yielding the title compound, MS m/e (%): 371 M⁺ (100%).

Example 258

2-Furan-2-yl-7-(5,6,7,8-tetrahydro-naphthalen-1-yloxy)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

A mixture of 1eq. 7-bromo-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine, 5eq. 5,6,7,8-tetrahydro-naphthalen-1-ol and a catalytic amount of Cs₂CO₃ in 200ul N-methyl-pyrrolidone was heated for 2h to 160°. The mixture was, after filtration, purified with

reversed phase column chromatography eluting with an acetonitrile/water gradient yielding the title compound, MS m/e (%): 346 M+H⁺ (100%).

Example 259

2-Furan-2-yl-7-p-tolyloxy-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine (RO-69-2954/000)

- 5 A mixture of 1eq. 7-bromo-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine, 5eq. p-methyl-phenol and a catalytic amount of Cs₂CO₃ in 200μl N-methyl-pyrrolidon was heated for 2h to 160°. The mixture was, after filtration, purified with reversed phase column chromatography eluting with an acetonitrile/water gradient yielding the title compound, MS m/e (%): 306 M+H⁺ (100%).

10

Example 260

7-(3-Fluoro-phenoxy)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

- A mixture of 1eq. 7-bromo-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine, 5eq. m-fluoro-phenol and a catalytic amount of Cs₂CO₃ in 200μl N-methyl-pyrrolidon was heated for 2h to 160°. The mixture was, after filtration, purified with reversed phase column
15 chromatography eluting with an acetonitrile/water gradient yielding the title compound, MS m/e (%): 310 M+H⁺ (100%).

Example 261

2-Furan-2-yl-7-(5,6,7,8-tetrahydro-naphthalen-2-yloxy)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

- 20 A mixture of 1eq. 7-bromo-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine, 5eq. 5,6,7,8-tetrahydro-naphthalen-2-ol and a catalytic amount of Cs₂CO₃ in 200μl N-methyl-pyrrolidon was heated for 2h to 160°. The mixture was, after filtration, purified with reversed phase column chromatography eluting with an acetonitrile/water gradient yielding the title compound, MS m/e (%): 346 M+H⁺ (100%).

25

Example 262

7-(6-Methyl-pyridin-2-ylmethoxy)-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

- A mixture of 1eq. 7-bromo-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine, 5eq. (6-methyl-pyridin-2-yl)-methanol and a catalytic amount of Cs₂CO₃ in 200μl N-methyl-pyrrolidon was heated for 2h to 160°. The mixture was, after filtration, purified with
30 reversed phase column chromatography eluting with an acetonitrile/water gradient yielding the title compound, MS m/e (%): 332 M+H⁺ (100%).

Example 263

7-Phenoxy-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine





- A mixture of 1eq. 7-bromo-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine, 5eq. phenol and a catalytic amount of Cs_2CO_3 in 200 μl N-methyl-pyrrolidon was heated for 2h to 160°. The mixture was, after filtration, purified with reversed phase column chromatography eluting with an acetonitrile/water gradient yielding the title compound, MS m/e (%): 303 $\text{M}+\text{H}^+$ (100%).













Example 264













4-(3,4-Dichloro-phenyl)-pyridine-2,6-diamine









- A mixture of 40.5mg (0.21 mmol) 2,6-diamino-4-bromo-pyridine, 90.5mg (0.47mmol) 3,4-dichloro-phenyl-boronic acid, 7.8mg (0.01mmol) Dichloro(1,1'-bis(diphenylphosphino) ferrocene)palladium (II) dichloromethane adduct and 0.3ml 2M Na_2CO_3 in 1 ml dimethoxyethane was heated to 80°C for 17 h. The mixture was filtered over silica washed with MeOH/DCM and concentrated. The residue was taken up in 1ml DMF and the totle compound was purified by reversed phase column chromatography eluting wit an acetonitrile/water gradient to yield 29mg (52%), MS m/e (%): 254 M^+ (100).

According to the method described in Example 264 further pyridine derivatives were synthesised as intermediates for triazolo-pyridine derivatives. The results are compiled in the following list comprising example 265 to example 300.

Example No.	Structure	name	MW	MS m/e (%)
265		4-(4-Ethyl-phenyl)-pyridine-2,6-diamine	213.3	$\text{M}+\text{H}^+$ (100)
266		4-(3,4-Dimethoxy-phenyl)-pyridine-2,6-diamine	245.3	$\text{M}+\text{H}^+$ (100)
267		4-(3-Fluoro-phenyl)-pyridine-2,6-diamine	203.2	$\text{M}+\text{H}^+$ (100)
268		4-(2,4-Dimethoxy-phenyl)-pyridine-2,6-diamine	245.3	$\text{M}+\text{H}^+$ (100)

Example No.	Structure	name	MW	MS m/e (%)
269		1-[4-(2,6-Diamino-pyridin-4-yl)-phenyl]-ethanone	227.3	M+H ⁺ (100)
270		4-(2-Fluoro-phenyl)-pyridine-2,6-diamine	203.2	M+H ⁺ (100)
271		4-Naphthalen-1-yl-pyridine-2,6-diamine	235.3	M+H ⁺ (100)
272		4-(4-Trifluoromethyl-phenyl)-pyridine-2,6-diamine	253.2	M+H ⁺ (100)
273		4-(3-Chloro-phenyl)-pyridine-2,6-diamine	219.7	M ⁺ (100)
274		4-(4-Methylsulfanyl-phenyl)-pyridine-2,6-diamine	231.3	M+H ⁺ (100)
275		4-m-Tolyl-pyridine-2,6-diamine	199.3	M+H ⁺ (100)
276		4-o-Tolyl-pyridine-2,6-diamine	199.3	M+H ⁺ (100)
277		4-(4-Vinyl-phenyl)-pyridine-2,6-diamine	211.3	M+H ⁺ (100)
278		4-Thiophen-3-yl-pyridine-2,6-diamine	191.3	M+H ⁺ (100)
279		4-(3-Trifluoromethyl-phenyl)-pyridine-2,6-diamine	253.2	M+H ⁺ (100)
280		4-(2-Methoxy-phenyl)-pyridine-2,6-diamine	215.3	M+H ⁺ (100)

Example No.	Structure	name	MW	MS m/e (%)
281		4-(4-Methoxy-phenyl)-pyridine-2,6-diamine	215.3	M+H ⁺ (100)
282		4-(4-Fluoro-phenyl)-pyridine-2,6-diamine	203.2	M+H ⁺ (100)
283		4-(3-Chloro-4-fluoro-phenyl)-pyridine-2,6-diamine	237.7	M ⁺ (100)
284		4-(3-Ethoxy-phenyl)-pyridine-2,6-diamine	229.3	M+H ⁺ (100)
285		4-(4-Chloro-phenyl)-pyridine-2,6-diamine	219.7	M ⁺ (100)
286		4-(2-Chloro-phenyl)-pyridine-2,6-diamine	219.7	M ⁺ (100)
287		4-(3-Methoxy-phenyl)-pyridine-2,6-diamine	215.3	M+H ⁺ (100)
288		N-[3-(2,6-Diamino-pyridin-4-yl)-phenyl]-acetamide	242.3	M+H ⁺ (100)
289		4-(4-Trifluoromethoxy-phenyl)-pyridine-2,6-diamine	269.2	M+H ⁺ (100)
290		4-p-Tolyl-pyridine-2,6-diamine	199.3	M+H ⁺ (100)
291		1-[5-(2,6-Diamino-pyridin-4-yl)-thiophen-2-yl]-ethanone	233.3	M+H ⁺ (100)
292		4-(2,6-Diamino-pyridin-4-yl)-benzoic acid ethyl ester	257.3	M+H ⁺ (100)

Example No.	Structure	name	MW	MS m/e (%)
293		N-[4-(2,6-Diamino-pyridin-4-yl)-phenyl]-acetamide	242.3	M+H ⁺ (100)
294		2-(2,6-Diamino-pyridin-4-yl)-benzonitrile	210.2	M+H ⁺ (100)
295		4-(4-Dimethylamino-phenyl)-pyridine-2,6-diamine	228.3	M+H ⁺ (100)
296		4-(2,6-Diamino-pyridin-4-yl)-N-methyl-benzamide	242.3	M+H ⁺ (100)
297		2-(2,6-Diamino-pyridin-4-yl)-benzoic acid ethyl ester	257.3	M+H ⁺ (100)
298		5-(2,6-Diamino-pyridin-4-yl)-2-methoxy-phenol	231.3	M+H ⁺ (100)
299		2,6-Dimethoxy-[3,4']bipyridinyl-2',6'-diamine	246.3	M+H ⁺ (100)
300		4-(3-Amino-phenyl)-pyridine-2,6-diamine	200.2	M+H ⁺ (100)

Example 301

2-(5-Bromo-furan-2-yl)-7-(3-chloro-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

To a solution of 28.7mg (0.11mmol) 4-(3-chloro-phenyl)-pyridine-2,6-diamine in 0.1 ml dioxane was added 26.7mg (0.12mmol) O-mesitylenesulfonylhydroxylamine (prepared from o-mesitylenesulfonylacetohydroxamate and HClO₄ (70%)) in 0.2ml dioxane at 5°C and kept there for 1h. Upon warming to 50°C 25.1mg (0.14mmol) 5-bromo-2-furaldehyde in 0.25ml dioxane and 0.05ml 1M KOH in dioxane was added and stirred at 50°C over night (12h). The title compound was, after addition of formic acid, purified by reversed phase column chromatography eluting with an acetonitrile/water gradient to yield 6.7mg (15%), MS m/e (%): 389 M+H⁺ (100).

According to the method described in Example 301 further triazolo-pyridine derivatives were synthesised. The results are compiled in the following list comprising example 302 to example 314.

Example No.	Structure	name	MW	MS m/e (%)
302		2-(5-Bromo-furan-2-yl)-7-m-tolyl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	369.2	M+H ⁺ (100)
303		2-(5-Bromo-furan-2-yl)-7-o-tolyl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	369.2	M+H ⁺ (100)
304		2-(5-Bromo-furan-2-yl)-7-(3-trifluoromethyl-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	423.2	M+H ⁺ (100)
305		2-(5-Bromo-furan-2-yl)-7-(2-methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	385.2	M+H ⁺ (100)
306		2-(5-Bromo-furan-2-yl)-7-(4-fluoro-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	373.2	M+H ⁺ (100)
307		2-(5-Bromo-furan-2-yl)-7-(4-chloro-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	389.6	M+H ⁺ (100)
308		2-(5-Bromo-furan-2-yl)-7-(3-methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	385.2	M+H ⁺ (100)

Example No.	Structure	name	MW	MS m/e (%)
309		2-(5-Bromo-furan-2-yl)-7-(4-trifluoromethoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	439.2	M+H ⁺ (100)
310		2-(5-Bromo-furan-2-yl)-7-(3-chloro-4-fluoro-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	407.6	M+H ⁺ (100)
311		2-(5-Bromo-furan-2-yl)-7-(3-ethoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	399.3	M+H ⁺ (100)
312		2-(5-Bromo-furan-2-yl)-7-p-tolyl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	369.2	M+H ⁺ (100)
313		4-[5-Amino-2-(5-bromo-furan-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-7-yl]-benzoic acid ethyl ester	427.3	M+H ⁺ (100)
314		2-(5-Bromo-furan-2-yl)-7-(2,6-dimethoxy-pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine	416.2	M+H ⁺ (100)

Example 315

7-(5-Butyl-pyridin-2-yl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

a) Mixture of (E)- and (Z)-3-(5-butyl-pyridin-2-yl)-acrylonitrile

- To a suspension of 1.66g (0.038mol) sodiumhydride (60% in oil) in 70 ml tetrahydrofurane and 70 ml dimethylformamide were added 21.2g (0.063mol) (cyanomethyl)triphenylphosphonium chloride. After stirring for 1 hour at room temperature a solution of 6.83g (0.042mol) 5-butyl-2- pyridinecarboxaldehyde in 150 ml dioxane were added and stirring was continued for 15 hours. Then 40 ml methanol were added, the solvents were evaporated and the residue chromatographed on silicagel with ethylacetate/hexane 1/4 to yield 4.39g (56%) (E)/(Z)-3-(5-butyl-pyridin-2-yl)-acrylonitrile as an oil. MS m/e (%): 186 (M^+ , 47), 143 (100).

b) 7-(5-Butyl-pyridin-2-yl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

- 10 The title compound, MS m/e (%): 334 ($M+H^+$, 100), was prepared in accordance with the general method of example 1 from 3-benzenesulfonylmethyl-5-furan-2-yl-1H-[1,2,4]triazole and (E)-3-(5-butyl-pyridin-2-yl)-acrylonitrile.

Example 316

7-(2-Fluoro-pyridin-4-yl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

- 15 a) (E) and (Z)-3-(2-Fluoro-pyridin-4-yl)-acrylonitrile

- To a suspension of 2.80g (0.038mol) sodiumhydride (60% in oil) in 120 ml tetrahydrofurane and 120 ml dimethylformamide were added 21.6g (0.064mol) (cyanomethyl)triphenylphosphonium chloride. After stirring for 1 hour at room temperature a solution of 4.00g (0.032mol) 2-fluoro-4-pyridinecarboxaldehyde in 35 ml tetrahydrofurane were added and stirring was continued for 2 days. Then 30 ml methanol were added, the solvents were evaporated and the residue chromatographed on silicagel with ethylacetate/hexane 1/2 to yield 0.45g (10%) (E)-and (Z)-3-(2-fluoro-pyridin-4-yl)-acrylonitrile as light yellow solid. MS m/e (%): 148 (M^+ , 100), 128 (43).

b) 7-(2-Fluoro-pyridin-4-yl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

- 25 The title compound, MS m/e (%): 296 ($M+H^+$, 100), was prepared in accordance with the general method of example 1 from 3-benzenesulfonylmethyl-5-furan-2-yl-1H-[1,2,4]triazole and 3-(2-fluoro-pyridin-4-yl)-acrylonitrile.

Example 317

7-(5-Chloro-pyridin-2-yl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

- 30 a) (E)-3-(5-Chloro-pyridin-2-yl)-acrylonitrile

To a suspension of 1.97g (0.045mol) sodiumhydride (60% in oil) in 60 ml tetrahydrofurane and 60 ml dimethylformamide were added 15.25g (0.045mol) (cyanomethyl)triphenylphosphonium chloride. After stirring for 1 hour at room temperature a solution of 6.39g (0.045mol) 5-chloro-2-pyridinecarboxaldehyde in 25 ml tetrahydrofurane were added and stirring was continued for 2 days. Then 15 ml methanol were added, the solvents were evaporated and the residue was chromatographed on aluminiumoxide with ethylacetate/hexane 3/7 to yield 4.09g (55%) (E)- 3-(5-chloro-pyridin-2-yl)-acrylonitrile as white solid. MS m/e (%): 164 (M^+ , 100), 137 (17), 113 (45).

b) 7-(5-Chloro-pyridin-2-yl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

- 10 The title compound, MS m/e (%): 312 ($M+H^+$, 100), was prepared in accordance with the general method of example 1 from 3-benzenesulfonylmethyl-5-furan-2-yl-1H-[1,2,4]triazole and 3-(5-chloro-pyridin-2-yl)-acrylonitrile.

Example 318

2-Furan-2-yl-7-(6-methoxy-pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

- 15 a) (E) and (Z)-3-(6-Methoxy-pyridin-3-yl)-acrylonitrile

A mixture of 5.94g (0.03mol) 5-bromo-2-methoxypyridine, 2.38 ml (0.036 mol) acrylonitrile, 15.1 ml (0.108 mol) triethylamine and 0.42g (0.0006 mol) bis(triphenylphosphine)palladium-(II)chloride in 120 ml dimethylformamide were stirred at 120 °C for 48 hours. The mixture was extracted with saturated aqueous sodiumbicarbonate solution and dried with sodiumsulfate. Chromatography on silicagel with hexane/ethylacetate 85/15 gave 2.47g (51%) (E)/(Z)-3-(6-methoxy-pyridin-3-yl)-acrylonitrile as a white solid. MS m/e (%): 160 (M^+ , 76), 159 (100), 131 (49).

b) 2-Furan-2-yl-7-(6-methoxy-pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

- 25 The title compound, MS m/e (%): 307 (M^+ , 100), was prepared in accordance with the general method of example 1 from 3-benzenesulfonylmethyl-5-furan-2-yl-1H-[1,2,4]triazole and 3-(6-methoxy-pyridin-2-yl)-acrylonitrile.

Example 319

4-(5-Amino-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-phenyl-benzenesulfonamide (69-0030)

- 30 a) 4-(2-Cyano-vinyl)-N-phenyl-benzenesulfonamide

- A mixture of 2.88g (0.009mol) 4-bromo-N-phenyl- benzenesulfonamide, 0.59g (0.011 mol) acrylonitrile, 4.65 ml (0.033 mol) triethylamine and 129g (0.0002 mol) bis(triphenylphosphine)palladium(II)chloride in 50 ml dimethylformamide were stirred at 120 °C for 72 hours. The mixture was extracted with saturated aqueous sodiumbicarbonate solution and dried with sodiumsulfate. Chromatography on silicagel with hexane/ethylacetate 7/3 gave 1.73g (69%) (E)/(Z)- 4-(2-cyano-vinyl)-N-phenyl- benzenesulfonamide as a white solid. MS m/e (%):MS m/e (%): 283 (M-H⁻, 100).

b) 4-(5-Amino-2-furan-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-phenyl- benzenesulfonamide

- 10 The title compound, MS m/e (%): 430 (M-H⁻, 100), was prepared in accordance with the general method of example 1 from 3-benzenesulfonylmethyl-5-furan-2-yl-1H-[1,2,4]triazole and 4-(2-cyano-vinyl)-N-phenyl-benzenesulfonamide

Example 320:

- 2-Furan-2-yl-7-[4-(4-methyl-piperazine-1-sulfonyl)-phenyl]-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

a) 3-[4-(4-Methyl-piperazine-1-sulfonyl)-phenyl]-acrylonitrile

- A mixture of 24.1g (0.068mol) 1-[(4-bromophenyl)sulfonyl]-4-methyl- piperazine, 5.38 ml acrylonitrile, 18.9 ml (0.26 mol) triethylamine and 0.95g (0.001 mol) bis(triphenylphosphine)palladium(II)chloride in 380 ml dimethylformamide were stirred at 120 °C for 72 hours. The mixture was extracted with saturated aqueous sodiumbicarbonate solution and dried with sodiumsulfate. Chromatography on silicagel with dichloromethane/methanol 98/2 gave 15.2g (77%) (E)/(Z)- 3-[4-(4-methyl-piperazine-1-sulfonyl)-phenyl]-acrylonitrile as a light yellow solid. MS m/e (%): 292 (M+H⁺, 100).

- 25 b) 2-Furan-2-yl-7-[4-(4-methyl-piperazine-1-sulfonyl)-phenyl]-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

The title compound, MS m/e (%): 439 (M+H⁺, 100), was prepared in accordance with the general method of example 1 from 3-benzenesulfonylmethyl-5-furan-2-yl-1H-[1,2,4]triazole and 3-[4-(4-methyl-piperazine-1-sulfonyl)-phenyl]-acrylonitrile.

Example 321

2-(2,4-Difluoro-phenyl)-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

a) 2,4-Difluoro-benzoic acid (1-amino-2-benzenesulfonyl-ethylidene)-hydrazide

A suspension of 15.3g (0.058mol) 2-(phenylsulfonyl)-ethanimidic acid ethyl ester hydrochloride in 125 ml chloroform was treated with 58.1 ml 1N aqueous sodium hydroxide. 18 ml of a saturated aqueous sodiumbicarbonate solution was added and the mixture was extracted with chloroform. The extracts were combined and dried with sodium sulfate and the solvents were distilled off under reduced pressure. The resulting colorless oil was stirred together with 10.0g (0.058mol) 2,4-difluorobenzoic acid hydrazide in 110ml chloroform over night at 50°C. The resulting precipitate was filtered off and dried. A yield of 8.50g (42%) 2,4-difluoro-benzoic acid (1-amino-2-benzenesulfonyl-ethylidene)-hydrazide was obtained as white solid. MS m/e (%): 354 (M+H⁺, 100).

b) 3-Benzenesulfonylmethyl-5-(2,4-difluoro-phenyl)-1H-[1,2,4]triazole

8.0g (0.023mol) 2,4-Difluoro-benzoic acid (1-amino-2-benzenesulfonyl-ethylidene)-hydrazide were heated at 210°C for 20 minutes. The molten mass was then cooled, dissolved in 30 ml hot ethanol and stirred overnight at room temperature. The precipitated crystals were filtered off and dried to yield 5.35 g (71%) 3-benzenesulfonylmethyl-5-(2,4-difluoro-phenyl)-1H-[1,2,4]triazole as white solid, MS m/e (%): 336 (M+H⁺, 100).

c) 2-(2,4-Difluoro-phenyl)-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

The title compound, MS m/e (%): 323 (M⁺, 100), 303 (60), was prepared in accordance with the general method of example 1 from 3-benzenesulfonylmethyl-5-(2,4-difluoro-phenyl)-1H-[1,2,4]triazole and (E)/(Z)-3-pyridin-4-yl-acrylonitrile.

Example 322

2-(2,4-Difluoro-phenyl)-7-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

The title compound, MS m/e (%): 324 (M+H⁺, 100), was prepared in accordance with the general method of example 1 from 3-benzenesulfonylmethyl-5-(2,4-difluoro-phenyl)-1H-[1,2,4]triazole and (E)/(Z)-3-pyridin-2-yl-acrylonitrile.

Example 323

2-(2-Fluoro-phenyl)-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

a) 2-Fluoro-benzoic acid (1-amino-2-benzenesulfonyl-ethylidene)-hydrazide

A suspension of 15.2g (0.058mol) 2-(phenylsulfonyl)-ethanimidic acid ethyl ester hydrochloride in 160 ml chloroform was treated with 57.7 ml 1N aqueous sodium hydroxide. 80 ml of a saturated aqueous sodiumbicarbonate solution was added and the

mixture was extracted with chloroform. The extracts were combined and dried with sodium sulfate and the solvents were distilled off under reduced pressure. The resulting colorless oil was stirred together with 9.98g (0.063mol) 2-fluorobenzoic acid hydrazide in 65 ml chloroform over night at 50°C. The resulting precipitate was filtered off and dried. A
5 yield of 14.6g 2-fluoro-benzoic acid (1-amino-2-benzenesulfonyl-ethylidene)-hydrazide was obtained as white solid. MS m/e (%): 336 (M+H⁺, 100).

b) 3-Benzenesulfonylmethyl-5-(2-fluoro-phenyl)-1H-[1,2,4]triazole

14g (0.042mol) 2-fluoro-benzoic acid (1-amino-2-benzenesulfonyl-ethylidene)-hydrazide were heated at 210°C for 20 minutes. The molten mass was then cooled, dissolved in 40 ml
10 hot ethanol and stirred overnight at room temperature. The precipitated crystals were filtered off and dried to yield 11.4 g (86%) 3-benzenesulfonylmethyl-5-(2-fluoro-phenyl)-1H-[1,2,4]triazole as beige solid, MS m/e (%): 317 (M⁺, 2), 253(68), 176(100), 122(61).

c) 2-(2-Fluoro-phenyl)-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

The title compound, MS m/e (%):306(M+H⁺,100), was prepared in accordance with the
15 general method of example 1 from 3-benzenesulfonylmethyl-5-(2-fluoro-phenyl)-1H-[1,2,4]triazole and (E)/(Z)-3-pyridin-4-yl-acrylonitrile.

Example 324

2-(2-Fluoro-phenyl)-7-(6-methoxy-pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

The title compound, MS m/e (%):336(M+H⁺,100), was prepared in accordance with the
20 general method of example 1 from 3-benzenesulfonylmethyl-5-(2-fluoro-phenyl)-1H-[1,2,4]triazole and (E)/(Z)-3-(6-methoxy-pyridin-3-yl)-acrylonitrile.

Example 325

7-(2-Ethyl-pyridin-4-yl)-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

The title compound, MS m/e (%):316(M⁺,100), was prepared in accordance with the
25 general method of example 1 from 2-(5-benzenesulfonylmethyl-2H-[1,2,4]triazol-3-yl)-pyridine and (E)-3-(2-ethyl-pyridin-4-yl)-acrylonitrile.

Example 326

7-(2-Methyl-pyridin-4-yl)-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

The title compound, MS m/e (%):303 ($M+H^+$,100), was prepared in accordance with the general method of example 1 from 2-(5-benzenesulfonylmethyl-2H-[1,2,4]triazol-3-yl)-pyridine and (E)/(Z)-3-(2-methyl-pyridin-4-yl)-acrylonitrile.

Example 327

5 **7-(5-Ethyl-pyridin-2-yl)-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine**

a) (E)/(Z)-3-(5-Ethyl-pyridin-2-yl)-acrylonitrile

(E)/(Z)-3-(5-Ethyl-pyridin-2-yl)-acrylonitrile was obtained from 5-ethyl-2-pyridinecarboxaldehyde and (cyanomethyl)triphenylphosphonium chloride /sodiumhydride in THF as a liquid, MS m/e (%):158(M^+ ,100).

10 **b) 7-(5-Ethyl-pyridin-2-yl)-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine**

The title compound, MS m/e (%):317 ($M+H^+$,100), was prepared in accordance with the general method of example 1 from 2-(5-benzenesulfonylmethyl-2H-[1,2,4]triazol-3-yl)-pyridine and (E)/(Z)-3-(5-ethyl-pyridin-2-yl)-acrylonitrile.

Example 328

15 **2,7-Di-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine**

The title compound, MS m/e (%):289 ($M+H^+$,100), was prepared in accordance with the general method of example 1 from 2-(5-benzenesulfonylmethyl-2H-[1,2,4]triazol-3-yl)-pyridine and (E)/(Z)-3-pyridin-2-yl-acrylonitrile.

Example 329:

20 **2-Pyridin-2-yl-7-pyridin-3-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine**

The title compound, MS m/e (%):288 (M^+ ,100), was prepared in accordance with the general method of example 1 from 2-(5-benzenesulfonylmethyl-2H-[1,2,4]triazol-3-yl)-pyridine and (E)/(Z)-3-pyridin-3-yl-acrylonitrile.

Example 330

25 **2-Pyridin-3-yl-7-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine**

a) Nicotinic acid (1-amino-2-benzenesulfonyl-ethylidene)-hydrazide

A suspension of 23.6g (0.089mol) 2-(phenylsulfonyl)-ethanimidic acid ethyl ester hydrochloride in 300 ml chloroform was treated with 98 ml 1N aqueous sodium hydroxide.

- 200 ml of a saturated aqueous sodiumbicarbonate solution was added and the mixture was extracted with chloroform. The extracts were combined and dried with sodium sulfate and the solvents were distilled off under reduced pressure. The resulting colorless oil was stirred together with 13.5g (0.098mol) nicotinic acid hydrazide in 500ml dioxane over night at 50°C. The resulting precipitate was filtered off and dried. A yield of 15.5g (55%) nicotinic acid (1-amino-2-benzenesulfonyl-ethylidene)-hydrazide was obtained as white solid, MS m/e (%): 319 (M+H⁺, 100).

b) 3-(5-Benzenesulfonylmethyl-2H-[1,2,4]triazol-3-yl)-pyridine

- 15.0g (0.047mol) nicotinic acid (1-amino-2-benzenesulfonyl-ethylidene)-hydrazide were heated at 220°C for 20 minutes. The molten mass was then cooled, dissolved in 100 ml hot ethanol and stirred overnight at room temperature. The precipitated crystals were filtered off and dried to yield 13.6 g (96%) 3-(5-benzenesulfonylmethyl-2H-[1,2,4]triazol-3-yl)-pyridine as white solid, MS m/e (%): 300 (M⁺, 8), 236(99), 159 (100), 105(43), 77(35).

c) 2-Pyridin-3-yl-7-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

- 15 The title compound, MS m/e (%):289 (M+H⁺,100), was prepared in accordance with the general method of example 1 from 3-(5-benzenesulfonylmethyl-2H-[1,2,4]triazol-3-yl)-pyridine and (E)/(Z)-2-pyridin-2-yl-acrylonitrile.

Example 331

7-(5-Chloro-pyridin-2-yl)-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

- 20 a) 3-(5-Chloro-pyridin-2-yl)-acrylonitrile

3-(5-Chloro-pyridin-2-yl)-acrylonitrile was obtained from 5-chloro-picolinaldehyde and diethyl cyanomethyl-phosphonate/sodiumhydride in THF as a white solid, MS m/e (%):164(M⁺,100), 137(17), 113(45).

b) 7-(5-Chloro-pyridin-2-yl)-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

- 25 The title compound, MS m/e (%):323 (M+H⁺,100), was prepared in accordance with the general method of example 1 from 2-(5-benzenesulfonylmethyl-2H-[1,2,4]triazol-3-yl)-pyridine and (E)/(Z)- 3-(5-chloro-pyridin-2-yl)-acrylonitrile.

Example 332

7-(6-Chloro-pyridin-3-yl)-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

The title compound, MS m/e (%):323 ($M+H^+$,100), was prepared in accordance with the general method of example 1 from 2-(5-benzenesulfonylmethyl-2H-[1,2,4]triazol-3-yl)-pyridine and (E)/(Z)-3-(6-chloro-pyridin-3-yl)-acrylonitrile.

Example 333

5 7-(6-Morpholin-4-yl-pyridin-3-yl)-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

A solution of 0.10g (0.0003 mol) 7-(6-chloro-pyridin-3-yl)-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine in 15 ml morpholine were stirred at 130°C for 4 hours. Removal of the amine and chromatography on silicagel with dichloromethane/methanol 9/1 gave 0.07g (62%) 7-(6-morpholin-4-yl-pyridin-3-yl)-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine as beige solid, MS m/e (%):374 ($M+H^+$,100).

Example 334

7-(6-Isopropylamino-pyridin-3-yl)-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

15 A solution of 0.16g (0.00035mol) 7-(6-chloro-pyridin-3-yl)-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine in 80 ml isopropylamine were stirred at 150°C for 150 hours in an autoclav. Removal of the amine and chromatography on silicagel with dichloromethane/methanol 9/1 gave 0.05g (29%) 7-(6-isopropylamino-pyridin-3-yl)-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine as beige solid, MS m/e (%):346 ($M+H^+$,100).

Example 335

7-(6-Ethylamino-pyridin-3-yl)-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

The title compound, MS m/e (%):331 (M^+ ,100). was prepared from 7-(6-chloro-pyridin-3-yl)-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine and ethylamine as described for the previous example 334.

Example 336

7-(6-Chloro-pyridin-2-yl)-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

a) E-3-(6-Chloro-pyridin-2-yl)-acrylonitrile

E-3-(6-Chloro-pyridin-2-yl)-acrylonitrile was obtained from 6-chloro-2-pyridinecarboxaldehyde and diethyl cyanomethyl-phosphonate/sodiumhydride in THF as a white solid, MS m/e (%):164(M⁺,100), 137(14), 113(75).

b) 7-(6-Chloro-pyridin-2-yl)-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

- 5 The title compound, MS m/e (%):323 (M+H⁺,100), was prepared in accordance with the general method of example 1 from 2-(5-benzenesulfonylmethyl-2H-[1,2,4]triazol-3-yl)-pyridine and E-3-(6-chloro-pyridin-2-yl)-acrylonitrile.

Example 337

7-(6-Ethylamino-pyridin-2-yl)-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

- 10 The title compound, MS m/e (%):331 (M⁺,100). was prepared from 7-(6-chloro-pyridin-2-yl)-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine and ethylamine as described for the example 334.

Example 338

2-Methylsulfonyl-7-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

- 15 a) 1-[[1-Amino-2-(phenylsulfonyl)ethylidene] amino]-2-methyl-2-thiopseudourea (or tautomer)

A suspension of 211g (0.80mol) 2-(phenylsulfonyl)-ethanimidic acid ethyl ester hydrochloride in 2 l chloroform was treated with 801 ml 1N aqueous sodium hydroxide. 350 ml of a saturated aqueous sodiumbicarbonate solution was added and the mixture was
 20 extracted with chloroform. The extracts were combined and dried with sodium sulfate and the solvents were distilled off under reduced pressure. The resulting oil was dissolved in 450 ml ethanol and the solution was added to a suspension of 44.6g (0.82mol) sodiummethylate and 187g (0.80mol) methyl aminomethanehydrazonothioate hydroiodide. After 75 minutes at room temperature 4.8 l of a 3/1 water/saturated aqueous
 25 sodiumbicarbonate solution was added and the mixture was extracted with chloroform. The organic phase was dried with sodiumsulfate and the solvents were evaporated. Recrystallisation from 1.8 l ethanol gave 121 g (53%) 1-[[1-amino-2-(phenylsulfonyl)ethylidene]amino]-2-methyl-2-thiopseudourea (or tautomer), MS m/e (%): 287 (M+H⁺, 100), 270 (28).

- 30 b) 3-Benzenesulfonylmethyl-5-methylsulfonyl-1H-[1,2,4]triazole

83.0g (0.29mol) 1-[[1-Amino-2-(phenylsulfonyl)ethylidene]amino]-2-methyl-2-thiopseudourea in 830 ml 1N HCl were refluxed for 30 minutes. After cooling the product crystallised. It was filtered off, washed with water and dried at 50°C/vacuum. Yield: 67.4g (86%), white solid with melting point 160-161°C.

5 c) 2-Methylsulfanyl-7-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

The title compound, MS m/e (%):258 (M+H⁺,100), was prepared in accordance with the general method of example 1 from 3-benzenesulfonylmethyl-5-methylsulfanyl-1H-[1,2,4]triazole and (E)/(Z)-3-pyridin-2-yl-acrylonitrile.

Example 339

10 2-Pyrazol-1-yl-7-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

a) 2-Methanesulfinyl-7-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

8.66g (0.034mol) 2-Methylsulfanyl-7-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine in 850 ml dichloromethane were oxidised with a solution of 17.6g (0.067mol) 3-phenyl-2-(phenylsulfonyl)oxaziridine in 150 ml dichloromethane overnight. Chromatography on
15 aluminiumoxide (dichloromethane/ methanol 97:3) and on silicagel (ethylacetate/ methanol 9:1) yielded 5.2g (57%) 2-methanesulfinyl-7-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine, MS m/e (%):274 (M+H⁺,100).

b) 2-Pyrazol-1-yl-7-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

A mixture of 0.50g (0.002mol) 2-methanesulfinyl-7-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine and 0.33ml (0.002 mol) 1,8-diazabicyclo[5.4.0]undec-7-en in 12.5 g
20 molten pyrazole as solvent was stirred overnight at 120°C. Destillation of the solvent and chromatography on silicagel with ethylacetate/ methanol 95/5 gave 0.13g (26%) 2-pyrazol-1-yl-7-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine as a white solid, MS m/e (%):278 (M+H⁺,100).

25

Example 340

7-Pyridin-2-yl-2-[1,2,4]triazol-1-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

The title compound, MS m/e (%):279 (M+H⁺,100), was prepared in accordance with the method of example 339b) from 2-methanesulfinyl-7-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine and 1,8-diazabicyclo[5.4.0]undec-7-en in 1,2,4-triazole at 130°C.

Example 341

2-(2-Methyl-imidazol-1-yl)-7-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

The title compound, MS m/e (%):292 ($M+H^+$,100), was prepared in accordance with the method of example 339b) from 2-methanesulfinyl-7-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine and 1,8-diazabicyclo[5.4.0]undec-7-en in 2-methylimidazole at 170°C.

Example 342

2-Phenethyloxy-7-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

0.06 g (0.003mol) sodium in 50 ml 2-phenylethanol were stirred overnight at 60°C. 0.2g (0.0007mol) 2-methanesulfinyl-7-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine were added and stirring was continued at 160°C for 16 hours. Evaporation of the solvent and chromatography on silicagel with ethylacetate gave 0.2g (83%) 2-phenethyloxy-7-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine, MS m/e (%):332 ($M+H^+$,100).

Example 343

2-Pyridin-2-yl-7-thiophen-3-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

The title compound, MS m/e (%):294 ($M+H^+$,100). was prepared according to the procedure of example 92 from 7-bromo-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine and 3-thiophenboronic acid.

Example 344

2-Pyrazol-1-yl-7-pyridin-3-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

a) 2-Methylsulfonyl-7-pyridin-3-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

2-Methylsulfonyl-7-pyridin-3-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine, a white solid with melting point 161-163°C, was prepared in accordance with the general method of example 1 from 3-benzenesulfonylmethyl-5-methylsulfonyl-1H-[1,2,4]triazole and (E)/(Z)-3-pyridin-3-yl-acrylonitrile.

b) 2-Methanesulfinyl-7-pyridin-3-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

2-Methanesulfinyl-7-pyridin-3-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine, MS m/e (%):274 ($M+H^+$,100), was prepared in accordance with the method of example 339a)

from 2-methylsulfanyl-7-pyridin-3-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine and 3-phenyl-2-(phenylsulfonyl)oxaziridine.

c) 2-Pyrazol-1-yl-7-pyridin-3-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

The title compound, MS m/e (%): 277 (M^+ , 100), was prepared in accordance with the
5 method of example 339b) from 2-methanesulfinyl-7-pyridin-3-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine and 1,8-diazabicyclo[5.4.0]undec-7-en in pyrazole at 75°C.

Example 345

8-Benzenesulfonyl-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

The title compound, MS m/e (%): 341 ($M+H^+$, 100), was prepared in accordance with the
10 general method of example 1 from 3-benzenesulfonylmethyl-5-furan-2-yl-1H-[1,2,4]triazole and 3-methoxy-2-propenitrile.

Example 346

8-Benzenesulfonyl-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

The title compound, MS m/e (%): 351 (M^+ , 92), 286(100), 171(54), was prepared in
15 accordance with the general method of example 1 from 2-(5-benzenesulfonylmethyl-2H-[1,2,4]triazol-3-yl)-pyridine and 3-methoxy-2-propenitrile.

Example 347

5-Amino-2-phenyl-[1,2,4]triazolo[1,5-a]pyridine-8-carbonitrile

The title compound, MS m/e (%): 235 (M^+ , 100), 208(10), 104(16), was prepared in
20 accordance with the general method of example 1 from (5-phenyl-2H-[1,2,4]triazol-3-yl)-acetonitrile and 3-methoxy-2-propenitrile.

Example 348

2-[1-(2,7-Di-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-1,4,5,6-tetrahydro-pyrimidin-2-yl]-benzoic acid

The title compound, MS m/e (%): 476 ($M+H^+$, 100), was prepared in accordance with the
25 general method of example 27 from 2,7-di-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine and N-(3-bromopropyl)-phthalimide.

Example 349

7-(5-Methoxy-pyridin-2-yl)-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

a) (E) and (Z)-3-(5-Methoxy-pyridin-2-yl)-acrylonitrile

To a suspension of 1.60 g (0.036 mol) sodiumhydride (55% in oil) in 70 ml
5 tetrahydrofurane and 50 ml dimethylformamide were added 12.32 g (0.036mol)
(cyanomethyl)triphenylphosphonium chloride. After sirring for 1 hour at room
temperature a solution of 6.39g (0.045mol) 5-chloro-2-pyridinecarboxaldehyde in 25 ml
tetrahydrofurane were added and stirring was continued for 1 day. Then 100 ml water were
added. It has been extracted three times with ethyl acetate and the organic phase was dried
10 over sodium sulfate. The solvents were evaporated and the residue was chromatographed
on silica gel with ethylacetate/hexane 1/4 to yield 4.90 g (65%) 3-(5-methoxy-pyridin-2-
yl)-acrylonitrile (E/Z = 2/5) as a yellow oil. MS m/e (%): 160 (M⁺, 100), 109 (34), 90 (36).

b) 7-(5-Methoxy-pyridin-2-yl)-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

The title compound, Mp.: 227-228° C, was prepared in accordance with the general
15 method of example 1 from 3-benzenesulfonylmethyl-5-pyridin-2-yl-1H-[1,2,4]triazole and
3-(5-methoxy-pyridin-2-yl)-acrylonitrile.

Example 350

7-Morpholin-4-yl-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

7-Bromo-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine (50 mg, 0.17 mmol) were
20 dissolved in 2 ml of morpholin and heated to 180° C for 16 h. Excess morpholin has been
evaporated and the residue was partitioned between water and methylene chloride (10 ml
each). The inorganic phase has been extracted twice with methylene chloride (10 ml) and
the combined organic phases were dried over sodium sulfate. The filtrate has been
evaporated and the residue was crystallized from dichloromethane to yield 7-morpholin-4-
25 yl-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine (33 mg, 65 %) as a white solid;
M.p.: 240-241° C.

Example 351


7-(4-Methyl-piperazin-1-yl)-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine

7-Bromo-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine (15 mg, 0.05 mmol) were
30 dissolved in 2 ml of N-methyl-piperazin and heated to 180° C for 16 h. Excess N-methyl-
piperazin has been evaporated and the residue was partitioned between water and ethyl

- acetate (10 ml each). The inorganic phase has been extracted twice with methylene chloride (10 ml) and the combined organic phases were dried over sodium sulfate. The filtrate has been evaporated and the residue was subjected to column chromatography on silica gel with ethyl acetate, then dichloromethane/methanol 9/1 and eventually
- 5 dichloromethane/methanol 4/1 as eluents to yield 7-(4-methyl-piperazin-1-yl)-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine (5.0 mg, 31 %) as a yellow solid. MS: (ISP) m/e 332 ($M+Na^+$, 25 %), 310 ($M+H^+$, 100 %).

Claims

1. A compound of the general formula



5 wherein

R^1 is a 5 or 6 membered heteroaryl group, containing 1 to 3 heteroatoms, selected from N, O or S, and which groups are optionally substituted by one or two substituents, which are lower alkyl, $-(CH_2)_nOH$, halogen or lower alkoxy, and wherein the heteroaryl groups may be optionally linked to the pyrazole ring via an alkylene or alkenylene group, or is

10

phenyl, optionally substituted by one or two substituents being lower alkyl, hydroxy-lower alkyl, halogen, hydroxy or lower alkoxy or is

$-O(CH_2)_n$ phenyl, benzofuryl, indolyl or benzothiophenyl, or is
 $-S$ -lower alkyl;

15 R^2 and R^4 are independently from each other hydrogen, cyano or $-S(O)_2$ -phenyl;

R^3 is hydrogen, halogen or is

a 5 or 6 membered heteroaryl group, containing 1 to 3 heteroatoms, selected from N, O or S, and which groups are optionally substituted by one or two substituents, which are lower alkyl, $-(CH_2)_n$ -aryl, hydroxy, halogen, lower alkoxy, morpholinyl, amino, lower alkylamino or $-C(O)NR'_2$, and wherein R' is lower alkyl or hydrogen, or is

20

phenyl, optionally substituted by one or two substituents being halogen, lower alkyl, lower alkoxy, amino, di-lower alkyl amino, CF_3 , $-OCF_3$, $-NHC(O)$ lower alkyl, cyano, $-C(O)$ -lower alkyl, $-C(O)O$ -lower alkyl, $-S$ -lower alkyl, $-S(O)_2NH$ -phenyl,
 25 $-S(O)_2$ -methylpiperazinyl; or is

- NR'R'', wherein R' and R'' are independently from each other hydrogen,
 -(CH₂)_nphenyl, which phenyl ring is optionally substituted by halogen or lower alkoxy, -CH(lower alkyl)-phenyl, indan-1-yl, 1,2,3,4-tetrahydro-naphthalen, or cycloalkyl; or is
- 5 -O-phenyl, which phenyl ring is optionally substituted by halogen, lower alkyl or lower alkoxy, -O-tetrahydronaphthalenyl or -O-CH₂-6-methyl-pyridin-2-yl; or is
- benzo[1,3]dioxolyl, -1H-indol-5-yl, naphthyl, benzofuran-2-yl,
 1,3,4,9-tetrahydro-b-carbolin-2-yl, piperidin-1-yl, pyrrolidin-1-yl,
 piperazin-4-yl-methyl or morpholinyl;
- 10 R⁵ is -NR₂, wherein R may be the same or different and is hydrogen, lower alkyl, phenyl, benzyl, -CO-lower alkyl, -CO-lower alkoxy, -lower alkenyl, -CO(CH₂)_n-phenyl or -COO(CH₂)_n-phenyl, wherein the phenyl ring is optionally substituted by CF₃, lower alkoxy, halogen or lower alkyl, -CO(CH₂)₃-NHCO-lower alkoxy, -
- 15 -(CH₂)_n-phenyl, wherein the phenyl ring is optionally substituted by lower alkoxy, CF₃ or halogen, or is 4,5-dihydro-1H-imidazol-2-yl-benzoic acid, 1,4,5,6-tetrahydro-pyrimidin-2-yl-benzoic acid or 4,5,6,7-tetrahydro-1H-[1,3]diazepin-2-yl-benzoic acid;
- n is 0 - 4
- and their pharmaceutically acceptable salts.
- 20 2. A compound of formula I, wherein
- R¹ is fur-2yl, lower alkenyl-fur-2-yl, benzofur-2yl, thiophen-2yl, thiazol-2yl, pyrrol-2yl, pyridin-2yl, pyridin-4yl, tetrahydrofuran-2yl, 1H-indol-3yl or phenyl, optionally substituted by one or two substituents being lower alkyl, hydroxy-lower alkyl, halogen, hydroxy or lower alkoxy;
- 25 R² and R⁴ are independently from each other hydrogen or cyano;
- R³ is hydrogen, halogen, pyridin-4yl, pyridin-3yl, pyridin-2yl, optionally substituted by lower alkyl, halogen or an oxy group; or phenyl, optionally substituted by halogen or CF₃;
- R⁵ is -NR₂, wherein R may be the same or different and is hydrogen, lower alkyl, phenyl,
- 30 benzyl, -CO-lower alkyl, -CO-lower alkoxy, -lower alkenyl, -CO(CH₂)_n-phenyl or

-COO(CH₂)_n-phenyl, wherein the phenyl ring is optionally substituted by CF₃, lower alkoxy, halogen or lower alkyl, -CO(CH₂)₃-NHCO-lower alkoxy, -(CH₂)_n-phenyl, wherein the phenyl ring is optionally substituted by lower alkoxy, CF₃ or halogen, or -(CH₂)_n-isoindole-1,3-dione;

5 R is hydrogen, lower alkyl, phenyl or benzyl and

n is 0 - 4

and their pharmaceutically acceptable salts.

3. A compound according to claim 1, wherein R⁵ is an unsubstituted amino group.

4. A compound according to claim 3, wherein R¹ is furyl.

10 5. A compound according to claim 4, which is

- 2-furan-2-yl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
- 2-furan-2-yl-7-pyridin-3-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
- 2-furan-2-yl-7-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
- 7-(3,5-bis-trifluoromethyl-phenyl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
- 15 7-(3,5-dichloro-phenyl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
- 7-(4-chloro-phenyl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
- 2-furan-2-yl-7-(2-methyl-pyridin-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
- 7-(2-ethyl-pyridin-4-yl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
- 2-furan-2-yl-7-(2-propyl-pyridin-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
- 20 2-furan-2-yl-7-(2-isopropyl-pyridin-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
- 7-(4-fluoro-phenyl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
- 2-furan-2-yl-7-(1-oxy-pyridin-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
- 5-amino-2-furan-2-yl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridine-6-carbonitrile,
- 7-(3-amino-phenyl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
- 25 7-(3,4-dimethoxy-phenyl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
- 7-(3,4-dichloro-phenyl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
- 7-(3-fluoro-phenyl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
- 1-[3-(5-amino-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-phenyl]-ethanone,
- 7-(2-fluoro-phenyl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
- 30 2-furan-2-yl-7-m-tolyl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
- 2-furan-2-yl-7-(4-methylsulfanyl-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
- 2-furan-2-yl-7-thiophen-3-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
- 2-furan-2-yl-7-(3-trifluoromethyl-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,

- 2-furan-2-yl-7-(3-methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
 N-[3-(5-amino-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-phenyl]-acetamide,
 2-furan-2-yl-7-(1H-indol-5-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
 N-[4-(5-amino-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methyl-phenyl]-
 5 acetamide,
 2-furan-2-yl-7-piperidin-1-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
 2-furan-2-yl-7-pyrrolidin-1-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
 2-furan-2-yl-7-(4-methyl-piperazin-1-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
 N7-(2-chloro-benzyl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridine-5,7-diamine,
 10 2-furan-2-yl-N7-(2-methoxy-benzyl)-[1,2,4]triazolo[1,5-a]pyridine-5,7-diamine,
 2-furan-2-yl-N7-(1-phenyl-ethyl)-[1,2,4]triazolo[1,5-a]pyridine-5,7-diamine,
 7-(5-butyl-pyridin-2-yl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
 7-(2-fluoro-pyridin-4-yl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
 7-(5-chloro-pyridin-2-yl)-2-furan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine or
 15 2-furan-2-yl-7-(6-methoxy-pyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine.

6. A compound according to claim 3, wherein R¹ is methyl substituted furyl.

7. A compound according to claim 6, which is

- 7-(4-chloro-phenyl)-2-(5-methyl-furan-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
 7-(3-methoxy-phenyl)-2-(5-methyl-furan-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
 20 7-(3,4-dimethoxy-phenyl)-2-(5-methyl-furan-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
 N-[3-[5-amino-2-(5-methyl-furan-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-7-yl]-phenyl]-acetamide or
 N-[4-[5-amino-2-(5-methyl-furan-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-7-yl]-phenyl]-
 25 acetamide.

8. A compound according to claim 3, wherein R¹ is pyridin-2-yl.

9. A compound according to claim 8, which is

- 7-(4-fluoro-phenyl)-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
 7-(3-methoxy-phenyl)-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
 30 7-(3-amino-phenyl)-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
 7-(2-ethyl-pyridin-4-yl)-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
 7-(2-methyl-pyridin-4-yl)-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
 7-(5-ethyl-pyridin-2-yl)-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
 2,7-di-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,

7-(5-chloro-pyridin-2-yl)-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine or
7-(6-chloro-pyridin-2-yl)-2-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine.

10. A compound according to claim 3, wherein R¹ is 5,6-dihydro-furan-2-yl.

11. A compound according to claim 10, which is

- 5 7-(3,4-dichloro-phenyl)-2-(4,5-dihydro-furan-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
2-(4,5-dihydro-furan-2-yl)-7-(3-fluoro-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
2-(4,5-dihydro-furan-2-yl)-7-(4-fluoro-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine,
2-(4,5-dihydro-furan-2-yl)-7-m-tolyl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine or
10 2-(4,5-dihydro-furan-2-yl)-7-(3-trifluoromethyl-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine.

12. A compound according to claim 3, wherein R¹ is pyrazol-1-yl.

13. A compound according to claim 12, which is

2-pyrazol-1-yl-7-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylamine.

- 15 14. A compound according to claim 1, wherein R⁵ is a substituted amino group.

15. A compound according to claim 14, wherein R¹ is phenyl.

16. A compound according to claim 15, which is

- but-3-enyl-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-amine,
ethyl-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-amine,
20 (2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-carbamic acid ethyl ester,
N-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-4-trifluoromethyl-
benzamide,
2-(2-chloro-phenyl)-N-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-
acetamide,
25 2-(2,4-dichloro-phenyl)-N-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-
acetamide,
N-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-2-(2-trifluoromethyl-
phenyl)-acetamide,
N-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-2-(4-trifluoromethyl-
30 phenyl)-acetamide,
3-phenyl-N-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-propionamide,
N-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-2-o-tolyl-acetamide,

2-(2-bromo-phenyl)-N-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-acetamide,

2-(2-iodo-phenyl)-N-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-acetamide,

5 3-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-ylcarbamoyl)-propyl]-carbamic acid tert-butyl ester,

2-(2-chloro-phenyl)-ethyl]-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-amine,

2-(2,4-dichloro-phenyl)-ethyl]-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-amine,

(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-(4-trifluoromethyl-benzyl)-amine,


(3-phenyl-propyl)-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-amine or diethyl-(2-phenyl-7-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-5-yl)-amine.

15 17. A medicament containing one or more compounds as claimed in any one of claims 1 – 16 and pharmaceutically acceptable excipients.


18. A medicament according to claim 17 for the treatment of diseases related to the adenosine receptor.

19. A process for preparing a compound of formula I as defined in claim 1, which
20 process comprises

a) reacting a compound of formula




with a compound of formula



25 to a compound of formula


- 96 -



wherein $R^1 - R^4$ have the significances given in claim 1, or

- b) substituting one or two hydrogen atoms of the amino group in formula I-1 by R, which is lower alkyl, phenyl, benzyl, -CO-lower alkyl, -CO-lower alkoxy, -lower alkenyl, -CO(CH₂)_n-phenyl or -COO(CH₂)_n-phenyl, wherein the phenyl ring is optionally substituted by CF₃, lower alkoxy, halogen or lower alkyl, -CO(CH₂)₃-NHCO-lower alkoxy, -(CH₂)_n-phenyl, wherein the phenyl ring is optionally substituted by lower alkoxy, CF₃ or halogen, or

- c) reacting a compound of formula



with a compound of formula



to a compound of formula I-1, wherein $R^1 - R^4$ have the significances given in claim 1, or

- d) modifying one or more substituents $R^1 - R^5$ within the definitions given above,

and

if desired, converting the compounds obtained into pharmaceutically acceptable acid addition salts.

20. A compound according to any one of claims 1 – 16, whenever prepared by a process as claimed in claim 18 or by an equivalent method.

21. The use of a compound in any one of claims 1 – 16 for the treatment of diseases related to the adenosine receptor or for the manufacture of corresponding medicaments.

22. The use of a compound in any one of claims 1 – 16 for the manufacture of corresponding medicaments for the treatment of diseases related to the adenosine A_{2A} receptor.

23. The invention as hereinbefore described.

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
15 March 2001 (15.03.2001)


PCT

(10) International Publication Number
WO 01/17999 A3

- (51) International Patent Classification⁷: C07D 471/04, A61K 31/437, A61P 25/00 // (C07D 471/04, 249:00, 221:00)
- (21) International Application Number: PCT/EP00/08372
- (22) International Filing Date: 28 August 2000 (28.08.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
99117578.7 6 September 1999 (06.09.1999) EP
- (71) Applicant: F. HOFFMANN-LA ROCHE AG [CH/CH];
124, Grenzacherstrasse, CH-4070 Basle (CH).
- (74) Agent: POPPE, Regina; 124 Grenzacherstrasse,
CH-4070 Basle (CH).
- (81) Designated States (*national*): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
- (88) Date of publication of the international search report:
6 December 2001
- (72) Inventors: HUBER TROTTMANN, Gerda; Hollenstrasse 211, CH-4247 Grindel (CH). HUNKELER, Walter; 32, Im Stigler, CH-4312 Magden (CH). JAKOB-ROETNE, Roland; Oberer Baselblick 37, 79595 Inzlingen (DE). KILPATRICK, Gavin, John; Lennox House, Caxton End, Eltisley, Cambridgeshire PE19 4TJ (GB). NETTEKOVEN, Matthias, Heinrich; Bandweg 10, 79639 Grenzach-Wyhlen (DE). RIEMER, Claus; Optizstrasse 5, 79110 Freiburg (DE).
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/17999 A3

(54) Title: AMINO-TRIAZOLOPYRIDINE DERIVATIVES



compounds are adenosine receptor ligands.

(57) Abstract: The invention relates to compounds of formula (I) wherein R¹ is a 5 or 6 membered heteroaryl group, optionally substituted and optionally linked to the pyrazole ring via an alkylene or alkenylene group, or is phenyl, optionally substituted or is -O(CH₂)_nphenyl, benzofuryl, indolyl or benzothiophenyl, or is -S-lower alkyl; R² and R⁴ are independently from each other hydrogen, cyano or -S(O)₂-phenyl; R³ is hydrogen, halogen or is heteroaryl or phenyl, optionally substituted -NR'R'' or -O-phenyl, or is -benzo[1,3]dioxolyl, -1H-indol-5-yl, naphthyl, benzofuran-2-yl, 1,3,4,9-tetrahydro-b-carboline-2-yl, piperidin-1-yl, pyrrolidin-1-yl, piperazin-4-yl-methyl or morpholinyl; R⁵ is -NR₂, n is 0-4 and their pharmaceutically acceptable salts. These

INTERNATIONAL SEARCH REPORT

Internal Application No

PCT/EP 00/08372

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D471/04 A61K31/437 A61P25/00 //(C07D471/04,249:00,
221:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	BARALDI, P. G. ET AL.: "Design, synthesis, and biological evaluation of a second generation of pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidines as potent and selective A2A adenosine receptor antagonists" J. MED. CHEM., vol. 41, 1998, pages 2126-2133, XP002163351 cited in the application compound 3	1-18, 20-23
Y	WO 94 14812 A (ZENECA LIMITED) 7 July 1994 (1994-07-07) abstract; claim 1; pages 7-8: A2A adenosine receptor affinity test --- -/--	1-18, 20-23

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

26 March 2001

Date of mailing of the international search report

27/04/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Alfaro Faus, I

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 00/08372

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>WO 99 43678 A (KYOWA HAKKO KOGYO CO., LTD.) 2 September 1999 (1999-09-02) abstract; examples, pages 17-20 -----</p>	<p>1-18, 20-23</p>

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 00/08372

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9414812 A	07-07-1994	AU 5656494 A	19-07-1994
		CN 1093708 A	19-10-1994
		HR 931512 A	31-12-1994
		MX 9400128 A	29-07-1994
		SI 9300674 A	30-06-1994
		US 5356894 A	18-10-1994
		ZA 9309045 A	22-06-1994
WO 9943678 A	02-09-1999	AU 2639299 A	15-09-1999